Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
transactivation	O
of	O
the	O
latent	B-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

Expression	O
of	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
latent	I-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
LMP-1	I-DNA
)	I-DNA
oncogene	I-DNA
is	O
regulated	O
by	O
the	O
EBV	B-protein
nuclear	I-protein
protein	I-protein
2	I-protein
(	I-protein
EBNA-2	I-protein
)	I-protein
transactivator	I-protein
.	O

EBNA-2	B-protein
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B-protein
DNA-binding	I-protein
protein	I-protein
J	B-protein
kappa	I-protein
and	O
is	O
recruited	O
to	O
promoters	B-DNA
containing	O
the	O
GTGGGAA	O
J	B-DNA
kappa	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

The	O
minimal	B-DNA
EBNA-2-responsive	I-DNA
LMP-1	I-DNA
promoter	I-DNA
includes	O
one	O
J	B-DNA
kappa-binding	I-DNA
site	I-DNA
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B-protein
kappa	I-protein
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B-protein
responsiveness	O
by	O
60	O
%	O
.	O

To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP-1	B-DNA
EBNA-2	I-DNA
response	I-DNA
element	I-DNA
(	O
E2RE	B-DNA
)	O
,	O
a	O
-236/-145	B-DNA
minimal	I-DNA
E2RE	I-DNA
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
previously	O
characterized	O
factors	O
J	B-protein
kappa	I-protein
,	O
PU.1	B-protein
,	O
and	O
AML1	B-protein
bind	O
to	O
the	O
LMP-1	B-DNA
E2RE	I-DNA
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B-protein
to	O
LBF7	B-protein
)	O
.	O

Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O

LBF4	B-protein
is	O
B-	O
and	O
T-cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	B-DNA
GGAA	I-DNA
core	I-DNA
sequence	I-DNA
as	O
shown	O
by	O
methylation	O
interference	O
.	O

LBF4	B-protein
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B-protein
.	O

LBF2	B-protein
was	O
found	O
only	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
and	O
LBF7	B-protein
were	O
not	O
cell	O
type	O
specific	O
.	O

Mutations	O
of	O
the	O
AML1-	B-DNA
or	I-DNA
LBF4-binding	I-DNA
sites	I-DNA
had	O
no	O
effect	O
on	O
EBNA-2	B-protein
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	B-DNA
site	I-DNA
completely	O
eliminated	O
EBNA-2	B-protein
responses	O
.	O

A	O
gst-EBNA-2	B-protein
fusion	I-protein
protein	I-protein
specifically	O
depleted	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
and	O
bound	O
in	O
vitro	O
translated	O
PU.1	B-protein
,	O
providing	O
biochemical	O
evidence	O
for	O
a	O
direct	O
EBNA-2	B-protein
-PU.1	B-protein
interaction	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
the	O
LMP-1	B-DNA
promoter	I-DNA
is	O
dependent	O
on	O
interaction	O
with	O
at	O
least	O
two	O
distinct	O
sequence-specific	O
DNA-binding	B-protein
proteins	I-protein
,	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
or	O
LBF7	B-protein
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B-protein
responsiveness	O
.	O

JOURNAL	NULL
or	NULL
ViROLOGY	NULL
,	NULL
Jan.	NULL
1995	NULL
,	NULL
p.	NULL
253-262	NULL
0022-538	NULL
X/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

69	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Epstein-Barr	NULL
Virus	NULL
Nuclear	NULL
Protein	NULL
2	NULL
Transactivation	NULL
of	NULL
the	NULL
Latent	NULL
Membrane	NULL
Protein	NULL
1	NULL
Promoter	NULL
Is	NULL
Mediated	NULL
by	NULL
Jk	NULL
and	NULL
PU.1	NULL
ERIC	NULL
JOHANNSEN	NULL
,	NULL
EUGENE	NULL
KOH	NULL
,	NULL
GEORGE	NULL
MOSIALOS	NULL
,	NULL
XIAO	NULL
TONG	NULL
,	NULL
ELLIOTT	NULL
KIEFF	NULL
,	NULL
*	NULL
AND	NULL
STEVEN	NULL
R.	NULL
GROSSMAN	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Program	NULL
in	NULL
Virology	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
and	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
Received	NULL
22	NULL
August	NULL
1994/Accepted	NULL
23	NULL
September	NULL
1994	NULL
Expression	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
(	NULL
LMP-1	NULL
)	NULL
oncogene	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
EBV	NULL
nuclear	NULL
protein	NULL
2	NULL
(	NULL
EBNA-2	NULL
)	NULL
transactivator	NULL
.	NULL

EBNA-2	NULL
is	NULL
known	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
cellular	NULL
DNA-binding	NULL
protein	NULL
Jx	NULL
and	NULL
is	NULL
recruited	NULL
to	NULL
promoters	NULL
containing	NULL
the	NULL
GTGGGAA	NULL
Jx	NULL
recognition	NULL
sequence	NULL
.	NULL

The	NULL
minimal	NULL
EBNA-2-responsive	NULL
LMP-1	NULL
promoter	NULL
includes	NULL
one	NULL
Jx-binding	NULL
site	NULL
,	NULL
and	NULL
we	NULL
now	NULL
show	NULL
that	NULL
mutation	NULL
of	NULL
that	NULL
site	NULL
,	NULL
such	NULL
that	NULL
Jr	NULL
can	NULL
not	NULL
bind	NULL
,	NULL
reduces	NULL
EBNA-2	NULL
responsiveness	NULL
by	NULL
60	NULL
%	NULL
.	NULL

To	NULL
identify	NULL
other	NULL
factors	NULL
which	NULL
interact	NULL
with	NULL
the	NULL
LMP-1	NULL
EBNA-2	NULL
response	NULL
element	NULL
(	NULL
E2RE	NULL
)	NULL
,	NULL
a	NULL
-236/-145	NULL
minimal	NULL
E2RE	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
previously	NULL
characterized	NULL
factors	NULL
Jx	NULL
,	NULL
PU.1	NULL
,	NULL
and	NULL
AML1	NULL
bind	NULL
to	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
,	NULL
along	NULL
with	NULL
six	NULL
other	NULL
unidentified	NULL
factors	NULL
(	NULL
LBF2	NULL
to	NULL
LBF7	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
were	NULL
mapped	NULL
for	NULL
each	NULL
factor	NULL
.	NULL

LBF4	NULL
is	NULL
B-	NULL
and	NULL
T-cell	NULL
specific	NULL
and	NULL
recognizes	NULL
the	NULL
PU.1	NULL
GGAA	NULL
core	NULL
sequence	NULL
as	NULL
shown	NULL
by	NULL
methylation	NULL
interference	NULL
.	NULL

LBF4	NULL
has	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
105	NULL
kDa	NULL
and	NULL
is	NULL
probably	NULL
unrelated	NULL
to	NULL
PU.1	NULL
.	NULL

LBF2	NULL
was	NULL
found	NULL
only	NULL
in	NULL
epithelial	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
LBF3	NULL
,	NULL
LBF5	NULL
,	NULL
LBF6	NULL
,	NULL
and	NULL
LBF7	NULL
were	NULL
not	NULL
cell	NULL
type	NULL
specific	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
AML1-	NULL
or	NULL
LBF4-binding	NULL
sites	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
EBNA-2	NULL
transactivation	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
PU.1-binding	NULL
site	NULL
completely	NULL
eliminated	NULL
EBNA-2	NULL
responses	NULL
.	NULL

A	NULL
gst-EBNA-2	NULL
fusion	NULL
protein	NULL
specifically	NULL
depleted	NULL
PU.1	NULL
from	NULL
nuclear	NULL
extracts	NULL
and	NULL
bound	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
,	NULL
providing	NULL
biochemical	NULL
evidence	NULL
for	NULL
a	NULL
direct	NULL
EBNA-2-PU.1	NULL
interaction	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
the	NULL
LMP-1	NULL
promoter	NULL
is	NULL
dependent	NULL
on	NULL
interaction	NULL
with	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
sequence-specific	NULL
DNA-binding	NULL
proteins	NULL
,	NULL
Jx	NULL
and	NULL
PU.1	NULL
.	NULL

LBF3	NULL
,	NULL
LBFS5	NULL
,	NULL
LBF6	NULL
,	NULL
or	NULL
LBF7	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
,	NULL
since	NULL
their	NULL
binding	NULL
sites	NULL
also	NULL
contribute	NULL
to	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
protein	NULL
2	NULL
(	NULL
EBNA-2	NULL
)	NULL
regulates	NULL
virus	NULL
and	NULL
cell	NULL
gene	NULL
transcription	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
primary	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
(	NULL
8	NULL
,	NULL
18	NULL
)	NULL
.	NULL

One	NULL
critical	NULL
EBNA-2	NULL
function	NULL
is	NULL
to	NULL
regulate	NULL
transcription	NULL
of	NULL
the	NULL
EBV	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
oncogene	NULL
(	NULL
LMP-1	NULL
)	NULL
(	NULL
1	NULL
,	NULL
44	NULL
)	NULL
,	NULL
whose	NULL
expression	NULL
is	NULL
also	NULL
essential	NULL
for	NULL
primary	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
(	NULL
21	NULL
)	NULL
.	NULL

EBNA-2	NULL
response	NULL
elements	NULL
(	NULL
EZREs	NULL
)	NULL
have	NULL
been	NULL
characterized	NULL
upstream	NULL
of	NULL
the	NULL
EBV	NULL
LMP	NULL
-1	NULL
,	NULL
LMP	NULL
-2A	NULL
,	NULL
and	NULL
Cp	NULL
promoters	NULL
(	NULL
12	NULL
,	NULL
20	NULL
,	NULL
41	NULL
,	NULL
51	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
CD23	NULL
promoter	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Each	NULL
E2RE	NULL
includes	NULL
MNYYGTGG	NULL
GAA	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
cognate	NULL
sequence	NULL
for	NULL
the	NULL
cellular	NULL
DNA-binding	NULL
protein	NULL
Jx	NULL
(	NULL
16	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Jx	NULL
interacts	NULL
with	NULL
EBNA-2	NULL
in	NULL
vitro	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
48	NULL
)	NULL
and	NULL
thus	NULL
can	NULL
recruit	NULL
EBNA-2	NULL
to	NULL
E2REs	NULL
.	NULL

While	NULL
lacking	NULL
direct	NULL
sequence-specific	NULL
DNA-binding	NULL
activity	NULL
,	NULL
EBNA-2	NULL
has	NULL
an	NULL
acidic	NULL
activator	NULL
domain	NULL
that	NULL
can	NULL
interact	NULL
with	NULL
TFIIB	NULL
and	NULL
TAF40	NULL
and	NULL
increase	NULL
transcription	NULL
from	NULL
heterologous	NULL
promoters	NULL
(	NULL
7	NULL
,	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
E2REs	NULL
are	NULL
more	NULL
complex	NULL
than	NULL
expected	NULL
from	NULL
a	NULL
simple	NULL
model	NULL
whereby	NULL
only	NULL
Jx	NULL
cognate	NULL
sequences	NULL
are	NULL
necessary	NULL
to	NULL
direct	NULL
EBNA-2-responsive	NULL
promoters	NULL
.	NULL

Jk	NULL
is	NULL
ubiquitously	NULL
expressed	NULL
in	NULL
cell	NULL
lines	NULL
and	NULL
tissues	NULL
(	NULL
14	NULL
,	NULL
16	NULL
,	NULL
17	NULL
,	NULL
38	NULL
)	NULL
,	NULL
but	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
is	NULL
responsive	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
T	NULL
or	NULL
epithelial	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
LMP	NULL
LMP-2	NULL
,	NULL
Cp	NULL
,	NULL
and	NULL
CD23	NULL
minimal	NULL
E2REs	NULL
all	NULL
include	NULL
one	NULL
or	NULL
two	NULL
Jx	NULL
sites	NULL
but	NULL
can	NULL
not	NULL
be	NULL
limited	NULL
to	NULL
those	NULL
sites	NULL
and	NULL
still	NULL
maintain	NULL
EBNA-2	NULL
responsiveness	NULL
(	NULL
12	NULL
,	NULL
20	NULL
,	NULL
41	NULL
,	NULL
46	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
reporter	NULL
constructs	NULL
containing	NULL
four	NULL
tandem	NULL
Jx	NULL
sites	NULL
or	NULL
two	NULL
tandem	NULL
Cp	NULL
EZREs	NULL
were	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
and	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
75	NULL
Francis	NULL
St.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
732-7048	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
278-6964	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
ekief	NULL
@	NULL
bustoff.bwh.harvard.edu	NULL
.	NULL

253	NULL
not	NULL
EBNA-2	NULL
responsive	NULL
,	NULL
although	NULL
higher-order	NULL
oligomers	NULL
did	NULL
exhibit	NULL
E2RE	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
promoter-distal	NULL
end	NULL
of	NULL
the	NULL
LMP-1	NULL
EZ2RE	NULL
has	NULL
been	NULL
mapped	NULL
to	NULL
either	NULL
-234	NULL
bp	NULL
(	NULL
41	NULL
)	NULL
or	NULL
-214	NULL
bp	NULL
(	NULL
12	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
cap	NULL
site	NULL
.	NULL

The	NULL
two	NULL
likely	NULL
LMP-1	NULL
E2RE	NULL
Jx-binding	NULL
sites	NULL
are	NULL
at	NULL
-298	NULL
to	NULL
-290	NULL
or	NULL
-223	NULL
to	NULL
-213	NULL
.	NULL

One	NULL
of	NULL
these	NULL
sites	NULL
lies	NULL
within	NULL
a	NULL
-234	NULL
EZRE	NULL
,	NULL
and	NULL
neither	NULL
is	NULL
within	NULL
a	NULL
-214	NULL
E2RE	NULL
.	NULL

The	NULL
promoter-proximal	NULL
end	NULL
of	NULL
the	NULL
LMP1	NULL
E2RE	NULL
has	NULL
been	NULL
defined	NULL
to	NULL
be	NULL
-145	NULL
(	NULL
12	NULL
)	NULL
or	NULL
-92	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
objectives	NULL
of	NULL
these	NULL
experiments	NULL
are	NULL
to	NULL
more	NULL
precisely	NULL
define	NULL
the	NULL
role	NULL
of	NULL
Jx	NULL
in	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
and	NULL
to	NULL
identify	NULL
other	NULL
cellular	NULL
factors	NULL
that	NULL
may	NULL
be	NULL
involved	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

Cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
either	NULL
RPMI	NULL
1640	NULL
(	NULL
B-	NULL
and	NULL
T-cell	NULL
lines	NULL
)	NULL
or	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
DMEM	NULL
(	NULL
293	NULL
and	NULL
HeLa	NULL
cell	NULL
lines	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Plasmids	NULL
.	NULL

Plasmids	NULL
p-512/LMP	NULL
,	NULL
p-205/LMP	NULL
,	NULL
p-147/LMP	NULL
,	NULL
and	NULL
p-55/LMP	NULL
,	NULL
which	NULL
contain	NULL
inserts	NULL
beginning	NULL
at	NULL
the	NULL
indicated	NULL
upstream	NULL
positions	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
cap	NULL
site	NULL
)	NULL
of	NULL
the	NULL
B95-8	NULL
LMP-1	NULL
gene	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
the	NULL
promoterless	NULL
reporter	NULL
plasmid	NULL
pCAT3M	NULL
,	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
.	NULL

p-236/LMP	NULL
and	NULL
p-215/LMP	NULL
were	NULL
constructed	NULL
by	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
LMP-1	NULL
upstream	NULL
region	NULL
with	NULL
the	NULL
3	NULL
'	NULL
(	NULL
+39	NULL
)	NULL
LMP	NULL
primer	NULL
(	NULL
CCGGATCCCAGG	NULL
GCAGTGTGTCAGG	NULL
)	NULL
and	NULL
either	NULL
the	NULL
-236	NULL
(	NULL
GCGGATCCTTGGCCACCGCA	NULL
TTCCCA	NULL
)	NULL
or	NULL
-215	NULL
(	NULL
CCGGATCCGCTTGCCCCCCGGGGACC	NULL
)	NULL
5	NULL
'	NULL
primer	NULL
.	NULL

Plasmid	NULL
p-236AJx	NULL
contained	NULL
a	NULL
-236/LMP	NULL
insert	NULL
mutated	NULL
at	NULL
nucleotides	NULL
-219	NULL
to	NULL
-217	NULL
(	NULL
CAC-AGA	NULL
)	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
in	NULL
pCAT3M	NULL
.	NULL

The	NULL
5'-mutated	NULL
primer	NULL
(	NULL
-236AJx	NULL
)	NULL
used	NULL
in	NULL
the	NULL
PCR	NULL
was	NULL
GCGGATCCTTGGCCACCGCATTC-CAGAAGCTTGCCCC	NULL
.	NULL

Plasmid	NULL
p-236ALBF1	NULL
was	NULL
constructed	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
with	NULL
a	NULL
CAC-ACA	NULL
mutation	NULL
at	NULL
positions	NULL
-230	NULL
to	NULL
-228	NULL
,	NULL
using	NULL
the	NULL
5	NULL
'	NULL
-236ALBF1	NULL
primer	NULL
,	NULL
GCGGATCCTTGGCACACGCATTCCCA	NULL
.	NULL

Plasmid	NULL
p-236	NULL
APU.1	NULL
was	NULL
constructed	NULL
by	NULL
using	NULL
overlapping	NULL
primers	NULL
(	NULL
GTAGAAAGGGTCCG	NULL
TAGAAAGCG	NULL
and	NULL
CGCTTTCTACGGACCCTTTCTAC	NULL
)	NULL
to	NULL
generate	NULL
overlapping	NULL
products	NULL
mutated	NULL
at	NULL
nucleotides	NULL
-166	NULL
to	NULL
-164	NULL
(	NULL
TTC-GGA	NULL
)	NULL
,	NULL
which	NULL
were	NULL
then	NULL
extended	NULL
with	NULL
the	NULL
-236	NULL
and	NULL
LMP	NULL
primers	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pCAT3M	NULL
.	NULL

Plasmid	NULL
p-215APU.1	NULL
was	NULL
constructed	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
to	NULL
254	NULL
JOHANNSEN	NULL
ET	NULL
AL	NULL
.	NULL

p-236APU.1	NULL
,	NULL
except	NULL
that	NULL
the	NULL
-215	NULL
primer	NULL
was	NULL
used	NULL
as	NULL
the	NULL
5	NULL
'	NULL
primer	NULL
in	NULL
the	NULL
second	NULL
PCR	NULL
step	NULL
.	NULL

Plasmids	NULL
pTK-236/-145	NULL
,	NULL
pTK-215/-145	NULL
,	NULL
pTK-236/-196	NULL
,	NULL
pTK-215/-174	NULL
,	NULL
and	NULL
pTK-187/-145	NULL
contain	NULL
inserts	NULL
from	NULL
the	NULL
indicated	NULL
upstream	NULL
positions	NULL
of	NULL
the	NULL
B95-8	NULL
LMP-1	NULL
gene	NULL
cloned	NULL
as	NULL
PCR	NULL
products	NULL
or	NULL
synthetic	NULL
oligonucleotides	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pBLCAT2	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
minimal	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
5	NULL
'	NULL
primers	NULL
used	NULL
in	NULL
these	NULL
PCRs	NULL
are	NULL
described	NULL
above	NULL
(	NULL
primers	NULL
-236	NULL
and	NULL
-215	NULL
)	NULL
;	NULL
the	NULL
3	NULL
'	NULL
-145	NULL
primer	NULL
was	NULL
GCGGATCCTCTAGAATGTAAGCGTAGAAG	NULL
GGG	NULL
.	NULL

Plasmids	NULL
pTK-236AJx	NULL
,	NULL
pTK-236ALBF1	NULL
,	NULL
pTK-236APU.1	NULL
,	NULL
and	NULL
pTK-215	NULL
APU.1	NULL
contain	NULL
the	NULL
above-described	NULL
mutations	NULL
within	NULL
the	NULL
-236/-145	NULL
insert	NULL
that	NULL
was	NULL
PCR	NULL
amplified	NULL
with	NULL
the	NULL
above-described	NULL
mutant	NULL
5Â°	NULL
primers	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pBLCAT2	NULL
.	NULL

The	NULL
3	NULL
'	NULL
primer	NULL
for	NULL
these	NULL
products	NULL
was	NULL
the	NULL
-145	NULL
primer	NULL
except	NULL
for	NULL
pTK-236APU.1	NULL
and	NULL
pTK-215APU.1	NULL
,	NULL
for	NULL
which	NULL
it	NULL
was	NULL
GCGGATCC	NULL
TCTAGAATGTAAGCGTAGAAAGGGTCCGTAGAAAGCG	NULL
.	NULL

Plasmid	NULL
pTK-236ALBF4	NULL
contains	NULL
a	NULL
heptanucleotide	NULL
mutation	NULL
(	NULL
GCTTTCT-TAGG	NULL
GAG	NULL
)	NULL
at	NULL
positions	NULL
-175	NULL
to	NULL
-169	NULL
within	NULL
the	NULL
-236	NULL
to	NULL
-145	NULL
insert	NULL
and	NULL
was	NULL
PCR	NULL
amplified	NULL
with	NULL
the	NULL
-236	NULL
and	NULL
the	NULL
LBF4A	NULL
(	NULL
GCGGATCCATGTAAGCGTAG	NULL
AAAGGGGAAGTCTCCCTAGTGTGTITGT	NULL
)	NULL
primers	NULL
before	NULL
being	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pBLCAT2	NULL
.	NULL

All	NULL
LMP-1	NULL
promoter	NULL
constructs	NULL
were	NULL
verified	NULL
by	NULL
dideoxynucleotide	NULL
sequencing	NULL
.	NULL

Nuclear	NULL
extracts	NULL
and	NULL
EMSA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
Dignam	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Probes	NULL
were	NULL
prepared	NULL
from	NULL
annealed	NULL
synthetic	NULL
oligonucleotides	NULL
or	NULL
from	NULL
the	NULL
92-bp	NULL
BemHI	NULL
inserts	NULL
in	NULL
pTK-236	NULL
or	NULL
pTK-236APU.1	NULL
.	NULL

Plasmids	NULL
were	NULL
digested	NULL
with	NULL
BamHI	NULL
,	NULL
and	NULL
GATC	NULL
overhangs	NULL
were	NULL
filled	NULL
in	NULL
with	NULL
Klenow	NULL
by	NULL
using	NULL
a	NULL
[	NULL
Â°Â°P	NULL
]	NULL
JGTP	NULL
.	NULL

For	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
5	NULL
g	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
incubated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
reaction	NULL
buffer	NULL
[	NULL
10	NULL
mM	NULL
N-2-hydroxyethylpiperazine-NV'-2-ethanesulfonic	NULL
acid	NULL
(	NULL
HEPES	NULL
;	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
125	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
100	NULL
mg	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
per	NULL
ml	NULL
,	NULL
40	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
with	NULL
or	NULL
without	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
specific	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Probe	NULL
was	NULL
then	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
(	NULL
1	NULL
to	NULL
2	NULL
ng	NULL
or	NULL
5	NULL
X	NULL
10Â°	NULL
to	NULL
10	NULL
x	NULL
10Â°	NULL
cpm	NULL
per	NULL
reaction	NULL
}	NULL
,	NULL
which	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
antibody	NULL
was	NULL
preincubated	NULL
with	NULL
nuclear	NULL
extract	NULL
in	NULL
reaction	NULL
buffer	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
(	NULL
TBE	NULL
)	NULL
,	NULL
after	NULL
which	NULL
the	NULL
gel	NULL
was	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
film	NULL
.	NULL

PU.1	NULL
and	NULL
AML1	NULL
antibodies	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Protein	NULL
purification	NULL
.	NULL

Louckes	NULL
or	NULL
IB4	NULL
nuclear	NULL
extracts	NULL
from	NULL
18	NULL
liters	NULL
of	NULL
cells	NULL
were	NULL
diluted	NULL
with	NULL
4	NULL
volumes	NULL
of	NULL
20	NULL
mM	NULL
morpholineethanesulfonic	NULL
acid	NULL
(	NULL
MES	NULL
;	NULL
pH	NULL
6.2	NULL
)	NULL
-2	NULL
mM	NULL
dithiothreitol-1	NULL
mM	NULL
EDTA-10	NULL
%	NULL
glycerol-0.1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride-10	NULL
pg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
loaded	NULL
onto	NULL
an	NULL
S-Sepharose	NULL
column	NULL
,	NULL
and	NULL
step	NULL
eluted	NULL
with	NULL
100	NULL
to	NULL
1,000	NULL
mM	NULL
NaCl	NULL
.	NULL

For	NULL
LBF4	NULL
purification	NULL
,	NULL
peak	NULL
fractions	NULL
for	NULL
LBF4	NULL
EMSA	NULL
activity	NULL
after	NULL
S-Sepharose	NULL
were	NULL
pooled	NULL
and	NULL
fractionated	NULL
on	NULL
DNA	NULL
cellulose	NULL
;	NULL
then	NULL
peak	NULL
DNA	NULL
cellulose	NULL
fractions	NULL
(	NULL
0.3	NULL
M	NULL
NaCl	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
with	NULL
multimerized	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

BJAB	NULL
cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
electroporated	NULL
(	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
)	NULL
with	NULL
5	NULL
wg	NULL
of	NULL
pUC-B-galactosidase	NULL
,	NULL
5	NULL
to	NULL
15	NULL
ug	NULL
of	NULL
pSGS	NULL
or	NULL
pSGS-EBNA-2	NULL
,	NULL
and	NULL
5	NULL
g	NULL
of	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
for	NULL
48	NULL
h	NULL
(	NULL
LMP	NULL
promoter	NULL
assays	NULL
)	NULL
or	NULL
65	NULL
h	NULL
(	NULL
TK	NULL
promoter	NULL
assays	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
activity	NULL
(	NULL
41	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
for	NULL
EBNA-2	NULL
,	NULL
by	NULL
Western	NULL
immunoblot	NULL
with	NULL
pE2	NULL
antibody	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Methylation	NULL
interference	NULL
assay	NULL
.	NULL

The	NULL
EcoRI-Sa/l	NULL
fragment	NULL
from	NULL
plasmid	NULL
pTK-236/-145	NULL
was	NULL
singly	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
Â°Â°P	NULL
]	NULL
JCTP	NULL
,	NULL
and	NULL
used	NULL
for	NULL
methylation	NULL
interference	NULL
assays	NULL
of	NULL
PU.1	NULL
and	NULL
LBF4	NULL
complexes	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
and	NULL
elution	NULL
from	NULL
SDS-PAGE	NULL
gels	NULL
.	NULL

PU.1	NULL
(	NULL
35	NULL
)	NULL
,	NULL
ets	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biochemicals	NULL
)	NULL
,	NULL
and	NULL
NFAT	NULL
-p	NULL
(	NULL
29	NULL
)	NULL
antibodies	NULL
used	NULL
in	NULL
Western	NULL
blot	NULL
experiments	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
.	NULL

LBF4	NULL
was	NULL
eluted	NULL
and	NULL
renatured	NULL
from	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
gel	NULL
slices	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
)	NULL
.	NULL

RESULTS	NULL
The	NULL
minimal	NULL
LMP-1	NULL
E2RE	NULL
requires	NULL
the	NULL
cooperation	NULL
of	NULL
at	NULL
least	NULL
two	NULL
discrete	NULL
elements	NULL
.	NULL

The	NULL
relative	NULL
contribution	NULL
of	NULL
Jx	NULL
to	NULL
the	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
LMP-1	NULL
promoter	NULL
was	NULL
investigated	NULL
with	NULL
CAT	NULL
reporter	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
which	NULL
contained	NULL
no	NULL
Jk	NULL
site	NULL
(	NULL
-215/LMP	NULL
)	NULL
,	NULL
the	NULL
-223	NULL
to	NULL
-213	NULL
site	NULL
(	NULL
-236/LMP	NULL
)	NULL
,	NULL
or	NULL
both	NULL
the	NULL
-223	NULL
to	NULL
-213	NULL
and	NULL
-298	NULL
to	NULL
-290	NULL
sites	NULL
(	NULL
-512/LMP	NULL
)	NULL
.	NULL

In	NULL
B	NULL
lymphocytes	NULL
,	NULL
p-236/LMP	NULL
,	NULL
and	NULL
p-512/	NULL
LMP	NULL
were	NULL
equally	NULL
EBNA-2	NULL
responsive	NULL
(	NULL
10-	NULL
versus	NULL
8.5-fold	NULL
[	NULL
Fig	NULL
.	NULL

1AÂ¥J	NULL
)	NULL
.	NULL

p-215/LMP	NULL
,	NULL
which	NULL
contains	NULL
no	NULL
J	NULL
sites	NULL
,	NULL
was	NULL
significantly	NULL
less	NULL
responsive	NULL
(	NULL
4.5-fold	NULL
)	NULL
,	NULL
and	NULL
p-205/LMP	NULL
,	NULL
p-147/LMP	NULL
,	NULL
and	NULL
p-55/LMP	NULL
showed	NULL
no	NULL
responsiveness	NULL
above	NULL
that	NULL
of	NULL
a	NULL
promoterless	NULL
vector	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
-215/LMP	NULL
construct	NULL
was	NULL
consistently	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
the	NULL
vector	NULL
control	NULL
but	NULL
significantly	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
the	NULL
J.	NULL
ViroL	NULL
.	NULL

Fold	NULL
Activation	NULL
A	NULL
440	NULL
9	NULL
_v	NULL
_s	NULL
2	NULL
Â«	NULL
3	NULL
R	NULL
Fold	NULL
Activation	NULL
B	NULL
a	NULL
cn	NULL
e	NULL
a	NULL
oa	NULL
-236	NULL
[	NULL
--	NULL
--	NULL
-|	NULL
145	NULL
-215	NULL
[	NULL
--	NULL
-	NULL
-145	NULL
-236	NULL
[	NULL
|	NULL
--	NULL
-|	NULL
-196	NULL
215	NULL
|	NULL
--	NULL
174	NULL
187	NULL
|-	NULL
145	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

EBNA-2	NULL
responsiveness	NULL
in	NULL
the	NULL
LMP-1	NULL
upstream	NULL
region	NULL
.	NULL

EBNA-2	NULL
induced	NULL
increases	NULL
in	NULL
CAT	NULL
activity	NULL
in	NULL
BJAB	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
LMP1	NULL
promoter-CAT	NULL
reporter	NULL
plasmid	NULL
(	NULL
A	NULL
)	NULL
or	NULL
with	NULL
an	NULL
LMP1	NULL
regulatory	NULL
fragment	NULL
upstream	NULL
of	NULL
an	NULL
HSV	NULL
TK	NULL
promoter-CAT	NULL
reporter	NULL
plasmid	NULL
(	NULL
B	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
with	NULL
a	NULL
cotransfected	NULL
EBNA-2	NULL
expression	NULL
vector	NULL
is	NULL
compared	NULL
with	NULL
CAT	NULL
activity	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
without	NULL
EBNA-2	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
by	NULL
using	NULL
a	NULL
cotransfected	NULL
simian	NULL
virus	NULL
40	NULL
carly	NULL
promot-er-driven	NULL
B-galactosidase	NULL
expression	NULL
plasmid	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
deviation	NULL
of	NULL
values	NULL
in	NULL
independent	NULL
assays	NULL
.	NULL

-236/LMP	NULL
construct	NULL
.	NULL

These	NULL
data	NULL
therefore	NULL
show	NULL
that	NULL
one	NULL
Jx	NULL
site	NULL
is	NULL
necessary	NULL
for	NULL
full	NULL
EBNA-2	NULL
effect	NULL
and	NULL
confirm	NULL
the	NULL
previous	NULL
finding	NULL
that	NULL
a	NULL
-214/+40	NULL
LMP	NULL
promoter	NULL
without	NULL
either	NULL
Jx	NULL
site	NULL
is	NULL
still	NULL
EBNA-2	NULL
responsive	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
data	NULL
suggest	NULL
that	NULL
a	NULL
factor	NULL
interacting	NULL
with	NULL
sequence	NULL
between	NULL
-215	NULL
and	NULL
-205	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
residual	NULL
activity	NULL
of	NULL
the	NULL
-215/LMP	NULL
construct	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
3	NULL
'	NULL
boundary	NULL
of	NULL
the	NULL
LMP-1	NULL
EZRE	NULL
,	NULL
a	NULL
-236	NULL
to	NULL
-145	NULL
LMP-1	NULL
upstream	NULL
sequence	NULL
was	NULL
cloned	NULL
5	NULL
'	NULL
to	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
TK	NULL
minimal	NULL
promoter	NULL
in	NULL
a	NULL
CAT	NULL
reporter	NULL
construct	NULL
.	NULL

EBNA-2	NULL
induced	NULL
a	NULL
4.5-fold	NULL
activation	NULL
of	NULL
this	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
,	NULL
which	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
4-fold	NULL
induction	NULL
previously	NULL
demonstrated	NULL
for	NULL
the	NULL
-234	NULL
to	NULL
-92	NULL
element	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Also	NULL
consistent	NULL
with	NULL
previous	NULL
results	NULL
(	NULL
41	NULL
)	NULL
,	NULL
a	NULL
sequence	NULL
containing	NULL
just	NULL
the	NULL
Jrx-binding	NULL
site	NULL
(	NULL
-236	NULL
to	NULL
-196	NULL
)	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
mediate	NULL
EBNA-2	NULL
responsiveness	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
-215	NULL
to	NULL
-174	NULL
,	NULL
-187	NULL
to	NULL
-145	NULL
,	NULL
and	NULL
-215	NULL
to	NULL
-145	NULL
constructs	NULL
were	NULL
similarly	NULL
unresponsive	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
the	NULL
LMP1	NULL
E2RE	NULL
depends	NULL
on	NULL
cooperation	NULL
of	NULL
the	NULL
Jx	NULL
site	NULL
(	NULL
-223	NULL
to	NULL
-213	NULL
)	NULL
with	NULL
an	NULL
element	NULL
(	NULL
s	NULL
)	NULL
partially	NULL
or	NULL
fully	NULL
within	NULL
the	NULL
-215	NULL
to	NULL
-145	NULL
sequence	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
previous	NULL
experiments	NULL
in	NULL
which	NULL
sevenfold	NULL
activation	NULL
was	NULL
seen	NULL
(	NULL
12	NULL
)	NULL
,	NULL
the	NULL
-215	NULL
to	NULL
-145	NULL
construct	NULL
did	NULL
not	NULL
show	NULL
a	NULL
significant	NULL
EBNA-2	NULL
response	NULL
.	NULL

This	NULL
may	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
lower	NULL
sensitivity	NULL
of	NULL
the	NULL
TK	NULL
reporter	NULL
system	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
in	NULL
which	NULL
the	NULL
larger	NULL
-236	NULL
to	NULL
-145	NULL
construct	NULL
gave	NULL
only	NULL
4.5-fold	NULL
activation	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
previously	NULL
reported	NULL
20-fold	NULL
activation	NULL
for	NULL
this	NULL
sequence	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
results	NULL
with	NULL
the	NULL
-215/LMP	NULL
native	NULL
promoter	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
AMLI	NULL
Jx	NULL
PU.1	NULL
-145	NULL
\ACCGdTCGCGTAAGGGTGTCGAACGEGGCG~~~~GTGCGAAACATGAAGGEGAAAFATGCGAATGTAC	NULL
-168/-145	NULL
-168/-145A1	NULL
~176/-151	NULL
-176/-L51A1	NULL
=TAGGGAG	NULL
--	NULL
=	NULL
Lal	NULL
St	NULL
35	NULL
4	NULL
a	NULL
2	NULL
a	NULL
won	NULL
--	NULL
-	NULL
1	NULL
mon	NULL
3	NULL
8	NULL
4	NULL
+	NULL
3	NULL
S	NULL
a	NULL
cas	NULL
olialinl	NULL
\o	NULL
\p	NULL
b	NULL
t-	NULL
ccs	NULL
a	NULL
m	NULL
To	NULL
2	NULL
vo	NULL
-	NULL
G	NULL
6	NULL
5	NULL
ToGo	NULL
Â§	NULL
4	NULL
to	NULL
+	NULL
t+	NULL
+o	NULL
+	NULL
+o	NULL
+	NULL
CP	NULL
+	NULL
+	NULL
+	NULL
=o	NULL
m	NULL
D	NULL
8	NULL
.	NULL

(	NULL
A	NULL
___|	NULL
A	NULL
--	NULL
-+	NULL
Â»	NULL
qHu	NULL
lin	NULL
a	NULL
â	NULL
a	NULL
||	NULL
gPU.4ss	NULL
bined	NULL
bud	NULL
3LBF4	NULL
â¬-ITT	NULL
â¬	NULL
'	NULL
CâPU.1â	NULL
â	NULL
bo	NULL
ls	NULL
jet	NULL
daga	NULL
A	NULL
u	NULL
Al	NULL
u	NULL
d	NULL
=~	NULL
c	NULL
p	NULL
cst	NULL
10	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
80	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

PU.1	NULL
binds	NULL
to	NULL
the	NULL
minimal	NULL
LMP-1	NULL
E2RE	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
EBV	NULL
LMP-1	NULL
gene	NULL
.	NULL

Numbering	NULL
is	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
cap	NULL
site	NULL
(	NULL
B95-8	NULL
virus	NULL
[	NULL
3	NULL
,	NULL
13	NULL
]	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
conforming	NULL
to	NULL
PU.1	NULL
,	NULL
AML1	NULL
,	NULL
and	NULL
Jx	NULL
consensus	NULL
sequences	NULL
are	NULL
boxed	NULL
.	NULL

Native	NULL
and	NULL
mutated	NULL
competitor	NULL
oligonucleotides	NULL
used	NULL
in	NULL
the	NULL
EMSA	NULL
experiments	NULL
in	NULL
panel	NULL
B	NULL
are	NULL
shown	NULL
underneath	NULL
the	NULL
native	NULL
sequence	NULL
.	NULL

=	NULL
,	NULL
native	NULL
nucleotide	NULL
.	NULL

Mutated	NULL
nucleotides	NULL
are	NULL
displayed	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
EBV-negative	NULL
BJAB	NULL
cells	NULL
(	NULL
left	NULL
)	NULL
or	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
(	NULL
right	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
and	NULL
2	NULL
,	NULL
-236	NULL
to	NULL
-145	NULL
LMP-1	NULL
probe	NULL
without	NULL
or	NULL
with	NULL
nuclear	NULL
extract	NULL
,	NULL
respectively	NULL
;	NULL
3	NULL
through	NULL
6	NULL
,	NULL
probe	NULL
with	NULL
nuclear	NULL
extract	NULL
and	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
indicated	NULL
oligonucleotides	NULL
;	NULL
7	NULL
through	NULL
9	NULL
,	NULL
probe	NULL
with	NULL
nuclear	NULL
extract	NULL
plus	NULL
an	NULL
irrelevant	NULL
antibody	NULL
(	NULL
AP2	NULL
)	NULL
,	NULL
nuclear	NULL
extract	NULL
plus	NULL
PU.1	NULL
antibody	NULL
,	NULL
and	NULL
nuclear	NULL
extract	NULL
plus	NULL
PU.1	NULL
antibody	NULL
plus	NULL
a	NULL
PU.1	NULL
competitor	NULL
oligonucleotide	NULL
,	NULL
respectively	NULL
;	NULL
10	NULL
through	NULL
13	NULL
,	NULL
probe	NULL
incubated	NULL
with	NULL
a	NULL
reticulocyte	NULL
lysate	NULL
programmed	NULL
with	NULL
a	NULL
T3	NULL
PU.1	NULL
expression	NULL
vector	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Lanes	NULL
11-13	NULL
are	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
competitor	NULL
oligonucleotide	NULL
listed	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
PU.1	NULL
,	NULL
LBF4	NULL
,	NULL
and	NULL
PU.1	NULL
supershifted	NULL
(	NULL
PU.1ss	NULL
)	NULL
complexes	NULL
are	NULL
noted	NULL
.	NULL

construct	NULL
do	NULL
confirm	NULL
that	NULL
LMP-1	NULL
promoter	NULL
constructs	NULL
without	NULL
the	NULL
Jr	NULL
site	NULL
retain	NULL
residual	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

The	NULL
minimal	NULL
LMP-1	NULL
E2RE	NULL
binds	NULL
multiple	NULL
factors	NULL
including	NULL
the	NULL
ets	NULL
protein	NULL
PU.1	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
-236	NULL
to	NULL
-145	NULL
minimal	NULL
EZRE	NULL
element	NULL
was	NULL
examined	NULL
for	NULL
binding	NULL
sites	NULL
of	NULL
known	NULL
transcription	NULL
factors	NULL
.	NULL

A	NULL
perfect	NULL
6-	NULL
of	NULL
6-bp	NULL
match	NULL
for	NULL
the	NULL
AML1	NULL
protein-binding	NULL
site	NULL
(	NULL
TGYGGT	NULL
[	NULL
30	NULL
]	NULL
)	NULL
was	NULL
found	NULL
between	NULL
-229	NULL
and	NULL
-224	NULL
,	NULL
and	NULL
an	NULL
11-	NULL
of	NULL
12-bp	NULL
match	NULL
to	NULL
a	NULL
PU.1-binding	NULL
site	NULL
(	NULL
AAAGGGGAAGTa	NULL
[	NULL
22	NULL
]	NULL
)	NULL
was	NULL
found	NULL
at	NULL
-169	NULL
to	NULL
-158	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

The	NULL
putative	NULL
AML1	NULL
site	NULL
is	NULL
immediately	NULL
5	NULL
``	NULL
to	NULL
the	NULL
consensus	NULL
Jr	NULL
site	NULL
agctGTGGGAA	NULL
(	NULL
16	NULL
)	NULL
at	NULL
-223	NULL
to	NULL
-213	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

AML1	NULL
is	NULL
the	NULL
human	NULL
homolog	NULL
of	NULL
the	NULL
mouse	NULL
PEAZ	NULL
factor	NULL
,	NULL
which	NULL
is	NULL
important	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
poly-omavirus	NULL
enhancer	NULL
and	NULL
is	NULL
also	NULL
the	NULL
target	NULL
of	NULL
translocations	NULL
in	NULL
a	NULL
number	NULL
of	NULL
human	NULL
leukemias	NULL
(	NULL
2	NULL
,	NULL
11	NULL
,	NULL
31	NULL
,	NULL
34	NULL
)	NULL
.	NULL

PU.1	NULL
is	NULL
an	NULL
ets	NULL
family	NULL
protein	NULL
important	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
macrophage-and	NULL
B-cell-specific	NULL
promoters	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
activity	NULL
for	NULL
the	NULL
hypothetical	NULL
AML1-	NULL
and	NULL
PU.1-binding	NULL
sites	NULL
and	NULL
to	NULL
identify	NULL
other	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
-236	NULL
EBNA-2	NULL
TRANSACTIVATION	NULL
OF	NULL
LMP-1	NULL
255	NULL
to	NULL
-145	NULL
EZRE	NULL
sequence	NULL
,	NULL
EMSAs	NULL
were	NULL
performed	NULL
with	NULL
B-cell	NULL
extracts	NULL
and	NULL
a	NULL
-236/-145	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

A	NULL
predominant	NULL
complex	NULL
and	NULL
a	NULL
second	NULL
,	NULL
less	NULL
abundant	NULL
complex	NULL
were	NULL
noted	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Overlapping	NULL
oligonucleotide	NULL
competitors	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
were	NULL
used	NULL
to	NULL
identify	NULL
the	NULL
binding	NULL
sites	NULL
of	NULL
these	NULL
factors	NULL
.	NULL

A	NULL
-168	NULL
to	NULL
-145	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
that	NULL
contains	NULL
the	NULL
PU.1	NULL
site	NULL
inhibited	NULL
the	NULL
most	NULL
abundant	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
a	NULL
-168	NULL
to	NULL
-145	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
PU.1	NULL
consensus	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
-168/-145A1	NULL
)	NULL
no	NULL
longer	NULL
inhibited	NULL
it	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

When	NULL
antibody	NULL
to	NULL
PU.1	NULL
(	NULL
35	NULL
)	NULL
was	NULL
added	NULL
to	NULL
a	NULL
mixture	NULL
of	NULL
nuclear	NULL
extract	NULL
and	NULL
probe	NULL
,	NULL
the	NULL
putative	NULL
PU.1	NULL
complex	NULL
disappeared	NULL
and	NULL
a	NULL
larger	NULL
,	NULL
``	NULL
supershifted	NULL
``	NULL
complex	NULL
appeared	NULL
,	NULL
whereas	NULL
control	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
competitor	NULL
-168	NULL
to	NULL
-145	NULL
oligonucleotide	NULL
specifically	NULL
inhibited	NULL
formation	NULL
of	NULL
the	NULL
supershifted	NULL
complex	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
vitro	NULL
translated	NULL
murine	NULL
PU.1	NULL
(	NULL
which	NULL
is	NULL
only	NULL
2	NULL
amino	NULL
acids	NULL
longer	NULL
than	NULL
human	NULL
PU.1	NULL
)	NULL
formed	NULL
a	NULL
complex	NULL
with	NULL
the	NULL
-236/-145	NULL
probe	NULL
which	NULL
had	NULL
the	NULL
same	NULL
mobility	NULL
as	NULL
the	NULL
putative	NULL
PU.1	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

The	NULL
recombinant	NULL
PU.1	NULL
EMSA	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
-168	NULL
to	NULL
-145	NULL
and	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotides	NULL
but	NULL
not	NULL
by	NULL
the	NULL
-168	NULL
to	NULL
-145A1	NULL
oligonucleotide	NULL
,	NULL
which	NULL
is	NULL
mutated	NULL
within	NULL
the	NULL
PU.1	NULL
site	NULL
(	NULL
lanes	NULL
11	NULL
to	NULL
13	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
predominant	NULL
EMSA	NULL
complex	NULL
observed	NULL
with	NULL
the	NULL
-236/-145	NULL
LMP-1	NULL
probe	NULL
and	NULL
B-lymphoma	NULL
cell	NULL
extracts	NULL
is	NULL
due	NULL
to	NULL
PU.1	NULL
.	NULL

The	NULL
other	NULL
major	NULL
-236	NULL
to	NULL
-145	NULL
EMSA	NULL
complex	NULL
,	NULL
LBF4	NULL
(	NULL
LMP	NULL
binding	NULL
factor	NULL
4	NULL
)	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
and	NULL
2B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
which	NULL
also	NULL
contains	NULL
the	NULL
PU.1	NULL
site	NULL
.	NULL

However	NULL
,	NULL
neither	NULL
the	NULL
smaller	NULL
-168	NULL
to	NULL
-145	NULL
PU.1	NULL
consensus	NULL
site	NULL
oligonucleotide	NULL
nor	NULL
a	NULL
partially	NULL
overlapping	NULL
-180	NULL
to	NULL
-158	NULL
oligonucleotide	NULL
inhibited	NULL
the	NULL
LBF4	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
3	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
nucleotides	NULL
-175	NULL
to	NULL
-169	NULL
in	NULL
the	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
-176/-151A1	NULL
)	NULL
partially	NULL
impaired	NULL
competition	NULL
for	NULL
LBF4	NULL
binding	NULL
,	NULL
but	NULL
PU.1	NULL
was	NULL
still	NULL
inhibited	NULL
effectively	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

All	NULL
other	NULL
mutations	NULL
within	NULL
this	NULL
region	NULL
showed	NULL
similar	NULL
effects	NULL
on	NULL
both	NULL
factors	NULL
(	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Neither	NULL
PU.1	NULL
nor	NULL
LBF4	NULL
bound	NULL
to	NULL
-236/-145	NULL
probe	NULL
mutated	NULL
at	NULL
the	NULL
PU.1	NULL
site	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
nucleotides	NULL
-166	NULL
to	NULL
-164	NULL
or	NULL
-160	NULL
to	NULL
-158	NULL
in	NULL
the	NULL
-236	NULL
to	NULL
-145	NULL
fragment	NULL
abolished	NULL
both	NULL
PU.1	NULL
and	NULL
LBFA4	NULL
competitor	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Mutations	NULL
at	NULL
either	NULL
-162	NULL
to	NULL
-161	NULL
or	NULL
-157	NULL
to	NULL
-151	NULL
within	NULL
the	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
PU.1	NULL
or	NULL
LBF4	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
these	NULL
data	NULL
with	NULL
wild-type	NULL
or	NULL
mutated	NULL
oligonucleotide	NULL
competitors	NULL
,	NULL
LBF4	NULL
must	NULL
bind	NULL
to	NULL
a	NULL
sequence	NULL
which	NULL
includes	NULL
the	NULL
PU.1	NULL
consensus	NULL
site	NULL
and	NULL
additional	NULL
5	NULL
``	NULL
sequence	NULL
that	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
PU.1	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

To	NULL
further	NULL
differentiate	NULL
PU.1-	NULL
and	NULL
LBF4-binding	NULL
sequences	NULL
,	NULL
guanosine	NULL
contacts	NULL
were	NULL
evaluated	NULL
by	NULL
methylation	NULL
interference	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
methylation	NULL
of	NULL
guanosines	NULL
at	NULL
positions	NULL
-163	NULL
and	NULL
-164	NULL
strongly	NULL
interfered	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
PU.1	NULL
and	NULL
LBF4	NULL
,	NULL
while	NULL
methylation	NULL
of	NULL
guanosine	NULL
at	NULL
position	NULL
-162	NULL
interfered	NULL
less	NULL
completely	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
.	NULL

These	NULL
interference	NULL
patterns	NULL
center	NULL
on	NULL
a	NULL
GGAA	NULL
core	NULL
(	NULL
-159	NULL
to	NULL
-162	NULL
)	NULL
which	NULL
is	NULL
characteristic	NULL
of	NULL
ets	NULL
family	NULL
DNA-binding	NULL
sites	NULL
,	NULL
and	NULL
the	NULL
putative	NULL
PU.1	NULL
methylation	NULL
intereference	NULL
pattern	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
reported	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
PU.1	NULL
is	NULL
a	NULL
subunit	NULL
of	NULL
LBF4	NULL
(	NULL
as	NULL
is	NULL
seen	NULL
with	NULL
the	NULL
PU.1-NF-EMS	NULL
complex	NULL
[	NULL
36	NULL
]	NULL
)	NULL
,	NULL
LBFA4	NULL
was	NULL
purified	NULL
from	NULL
IB4	NULL
cell	NULL
nuclear	NULL
extracts	NULL
by	NULL
sequential	NULL
cation	NULL
exchange	NULL
,	NULL
DNA-cellulose	NULL
,	NULL
and	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
,	NULL
using	NULL
EMSA	NULL
to	NULL
monitor	NULL
LBF4	NULL
activity	NULL
.	NULL

LBF4	NULL
eluted	NULL
from	NULL
S-Sepharose	NULL
in	NULL
500	NULL
mM	NULL
NaCl	NULL
,	NULL
whereas	NULL
PU.1	NULL
eluted	NULL
in	NULL
900	NULL
mM	NULL
NaCl	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
S-Sepharose	NULL
fraction	NULL
was	NULL
chro-matographed	NULL
on	NULL
a	NULL
nonspecific	NULL
DNA-cellulose	NULL
matrix	NULL
,	NULL
and	NULL
the	NULL
256	NULL
JOHANNSEN	NULL
ET	NULL
AL	NULL
.	NULL

BINDING	NULL
PU.1	NULL
LBF4	NULL
-236/-145	NULL
++	NULL
++	NULL
~236/-145A90.1	NULL
.	NULL

-	NULL
~236/-14542	NULL
-	NULL
-176/-151	NULL
++	NULL
++	NULL
-176/-15141	NULL
++	NULL
+	NULL
-176/~15142	NULL
++	NULL
++	NULL
-176/-15143	NULL
++	NULL
++	NULL
B	NULL
LBF4	NULL
PU.1	NULL
F	NULL
B	NULL
F	NULL
F	NULL
B	NULL
F	NULL
we	NULL
.	NULL

se	NULL
.	NULL

as	NULL
``	NULL
&	NULL
Â¢	NULL
t	NULL
#	NULL
81	NULL
P	NULL
i	NULL
â¬	NULL
v	NULL
#	NULL
rer	NULL
oo	NULL
oott	NULL
Â©	NULL
#	NULL
#	NULL
=	NULL
O0	NULL
-v	NULL
00	NULL
ttt	NULL
:	NULL
te	NULL
o	NULL
ame	NULL
.	NULL

a-	NULL
e	NULL
#	NULL
@	NULL
e	NULL
>	NULL
#	NULL
#	NULL
00	NULL
o	NULL
:	NULL
ve	NULL
@	NULL
e	NULL
|	NULL
I	NULL
.	NULL

I	NULL
,	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

LBF4	NULL
and	NULL
PU.1	NULL
bind	NULL
and	NULL
protect	NULL
the	NULL
same	NULL
core	NULL
nucleotides	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
competitors	NULL
used	NULL
to	NULL
investigate	NULL
PU.1-	NULL
and	NULL
LBF4-binding	NULL
sites	NULL
are	NULL
shown	NULL
beneath	NULL
the	NULL
corresponding	NULL
native	NULL
LMP1	NULL
-236	NULL
to	NULL
-145	NULL
sequence	NULL
.	NULL

The	NULL
PU.1-	NULL
and	NULL
LBF4-binding	NULL
sites	NULL
are	NULL
boxed	NULL
.	NULL

For	NULL
competitor	NULL
oligonucleotides	NULL
,	NULL
native	NULL
nucleotides	NULL
are	NULL
denoted	NULL
by	NULL
=	NULL
and	NULL
mutated	NULL
oligonucleotides	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
each	NULL
competitor	NULL
to	NULL
block	NULL
PU.1	NULL
or	NULL
LBF4	NULL
shifts	NULL
is	NULL
graded	NULL
as	NULL
noncompetition	NULL
(	NULL
-	NULL
)	NULL
,	NULL
weak	NULL
competition	NULL
(	NULL
+	NULL
)	NULL
,	NULL
or	NULL
competition	NULL
equal	NULL
to	NULL
unlabeled	NULL
probe	NULL
(	NULL
++	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Methylation	NULL
interference	NULL
with	NULL
a	NULL
-236	NULL
to	NULL
-145	NULL
LMP-1	NULL
E2RE	NULL
probe	NULL
and	NULL
LBF4	NULL
or	NULL
PU.1	NULL
S-Sepharose	NULL
column	NULL
fractions	NULL
of	NULL
a	NULL
BJAB	NULL
nuclear	NULL
extract	NULL
.	NULL

End-labeled	NULL
DNA	NULL
was	NULL
methylated	NULL
and	NULL
incubated	NULL
with	NULL
partially	NULL
purified	NULL
(	NULL
S-Sepharose	NULL
)	NULL
LBF4	NULL
or	NULL
PU.1	NULL
.	NULL

The	NULL
PU.1	NULL
and	NULL
LBF4	NULL
EMSA	NULL
complexes	NULL
and	NULL
corresponding	NULL
free	NULL
probe	NULL
bands	NULL
were	NULL
transferred	NULL
to	NULL
DEAE	NULL
paper	NULL
and	NULL
eluted	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
cleaved	NULL
with	NULL
piperidine	NULL
and	NULL
electrophoresed	NULL
in	NULL
a	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

F	NULL
and	NULL
B	NULL
indicate	NULL
free	NULL
or	NULL
bound	NULL
LBF4	NULL
or	NULL
PU.1	NULL
EMSA	NULL
complexes	NULL
,	NULL
respectively	NULL
.	NULL

Open	NULL
and	NULL
solid	NULL
circles	NULL
indicate	NULL
weak	NULL
and	NULL
strong	NULL
interference	NULL
with	NULL
LBF4	NULL
and	NULL
PU.1	NULL
binding	NULL
,	NULL
respectively	NULL
.	NULL

Corresponding	NULL
sequence	NULL
is	NULL
displayed	NULL
at	NULL
the	NULL
left	NULL
,	NULL
with	NULL
the	NULL
5	NULL
'	NULL
end	NULL
at	NULL
the	NULL
top	NULL
.	NULL

00	NULL
P880	NULL
!	NULL

T	NULL
e	NULL
e	NULL
0	NULL
n-Ha-nana	NULL
Â»	NULL
>	NULL
Â»	NULL
>	NULL
a	NULL
>	NULL
Â»	NULL
41i0a	NULL
>	NULL
Â»	NULL
>	NULL
anoa	NULL
>	NULL
Â»	NULL
>	NULL
Â»	NULL
>	NULL
Â»	NULL
a	NULL
>	NULL
Â»	NULL
-1000	NULL
>	NULL
Â»	NULL
>	NULL
40o4	NULL
>	NULL
0.3	NULL
M	NULL
NaCl	NULL
peak	NULL
LBF4	NULL
fraction	NULL
was	NULL
further	NULL
fractionated	NULL
on	NULL
a	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
column	NULL
containing	NULL
multimerized	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
(	NULL
16	NULL
,	NULL
43	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
size	NULL
of	NULL
LBF4	NULL
,	NULL
polypeptides	NULL
in	NULL
the	NULL
peak	NULL
LBF4	NULL
fraction	NULL
from	NULL
the	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
column	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
sliced	NULL
into	NULL
small	NULL
pieces	NULL
,	NULL
each	NULL
containing	NULL
proteins	NULL
of	NULL
a	NULL
defined	NULL
size	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
eluted	NULL
from	NULL
each	NULL
slice	NULL
,	NULL
renatured	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
EMSA	NULL
(	NULL
4	NULL
)	NULL
.	NULL

LBF4	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
gel	NULL
slice	NULL
harboring	NULL
a	NULL
105-kDa	NULL
protein	NULL
,	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
slices	NULL
from	NULL
above	NULL
,	NULL
and	NULL
was	NULL
detected	NULL
at	NULL
a	NULL
lower	NULL
concentration	NULL
in	NULL
slices	NULL
from	NULL
below	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
of	NULL
the	NULL
purified	NULL
protein	NULL
with	NULL
antibodies	NULL
directed	NULL
against	NULL
the	NULL
ets	NULL
domain	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
or	NULL
against	NULL
the	NULL
NF-ATp	NULL
protein	NULL
(	NULL
29	NULL
)	NULL
(	NULL
which	NULL
is	NULL
similar	NULL
in	NULL
size	NULL
and	NULL
recognizes	NULL
a	NULL
similar	NULL
DNA	NULL
sequence	NULL
)	NULL
showed	NULL
no	NULL
reactivity	NULL
with	NULL
p105/LBFA4	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
NF-ATp	NULL
and	NULL
ets	NULL
antibod-	NULL
J.	NULL
ViroL	NULL
.	NULL

A	NULL
3	NULL
|	NULL
-	NULL
105	NULL
I0	NULL
1	NULL
~	NULL
A4	NULL
w	NULL
)	NULL
ut	NULL
i	NULL
<	NULL
-	NULL
LBF4	NULL
102	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
size	NULL
of	NULL
LBF4	NULL
.	NULL

The	NULL
LBF4	NULL
peak	NULL
activity	NULL
fraction	NULL
from	NULL
a	NULL
sequence-specific	NULL
DNA	NULL
affinity	NULL
column	NULL
containing	NULL
a	NULL
multimerzied	NULL
-176	NULL
to	NULL
-151	NULL
oligonucleotide	NULL
was	NULL
fractionated	NULL
on	NULL
an	NULL
SDS-6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
silver-stained	NULL
lane	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

(	NULL
B	NULL
)	NULL
A	NULL
nonstained	NULL
lane	NULL
was	NULL
cut	NULL
into	NULL
slices	NULL
corresponding	NULL
to	NULL
different	NULL
protein	NULL
sizes	NULL
,	NULL
and	NULL
eluted	NULL
proteins	NULL
from	NULL
each	NULL
slice	NULL
were	NULL
tested	NULL
for	NULL
EMSA	NULL
activity	NULL
with	NULL
a	NULL
labeled	NULL
-176/-151	NULL
probe	NULL
.	NULL

A	NULL
sample	NULL
containing	NULL
the	NULL
peak	NULL
activity	NULL
of	NULL
LBF4	NULL
from	NULL
an	NULL
S-Sepharose	NULL
column	NULL
is	NULL
shown	NULL
in	NULL
lane	NULL
13	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
LBF4	NULL
and	NULL
free	NULL
probe	NULL
(	NULL
P	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

ies	NULL
did	NULL
,	NULL
however	NULL
,	NULL
react	NULL
with	NULL
the	NULL
expected	NULL
proteins	NULL
in	NULL
cell	NULL
extracts	NULL
and	NULL
in	NULL
other	NULL
column	NULL
fractions	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
PU.1	NULL
and	NULL
LBF4	NULL
are	NULL
distinct	NULL
polypeptides	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
same	NULL
core	NULL
sequence	NULL
,	NULL
although	NULL
the	NULL
LBF4-binding	NULL
site	NULL
is	NULL
larger	NULL
and	NULL
includes	NULL
sequence	NULL
5	NULL
'	NULL
to	NULL
the	NULL
PU.1	NULL
site	NULL
.	NULL

A	NULL
probe	NULL
mutated	NULL
for	NULL
PU.1	NULL
and	NULL
LBF4	NULL
binding	NULL
allows	NULL
resolution	NULL
of	NULL
additional	NULL
LMP-1	NULL
E2RE	NULL
EMSA	NULL
complexes	NULL
and	NULL
confirmation	NULL
that	NULL
AML1	NULL
is	NULL
LBFL	NULL
.	NULL

EMSA	NULL
with	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
with	NULL
a	NULL
-236/-145	NULL
probe	NULL
mutated	NULL
at	NULL
the	NULL
PU.1-	NULL
and	NULL
LBF4-binding	NULL
site	NULL
(	NULL
-236/-145APU.1	NULL
)	NULL
allowed	NULL
resolution	NULL
of	NULL
complexes	NULL
obscured	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
abundant	NULL
PU.1	NULL
and	NULL
LBF4	NULL
complexes	NULL
.	NULL

Five	NULL
novel	NULL
complexes	NULL
were	NULL
identified	NULL
with	NULL
this	NULL
probe	NULL
and	NULL
termed	NULL
LBF1	NULL
,	NULL
LBF3	NULL
,	NULL
LBFS5	NULL
,	NULL
LBF6	NULL
,	NULL
and	NULL
LBF7	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

A	NULL
sixth	NULL
complex	NULL
was	NULL
identical	NULL
in	NULL
size	NULL
to	NULL
the	NULL
expected	NULL
Jx	NULL
complex	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Overlapping	NULL
competitor	NULL
oligonucleotides	NULL
spanning	NULL
the	NULL
probe	NULL
sequence	NULL
were	NULL
then	NULL
used	NULL
to	NULL
map	NULL
the	NULL
approximate	NULL
binding	NULL
site	NULL
for	NULL
each	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
sites	NULL
were	NULL
further	NULL
defined	NULL
by	NULL
mutations	NULL
within	NULL
competitor	NULL
oligonucleotides	NULL
(	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

The	NULL
Jx	NULL
and	NULL
LBF1	NULL
complexes	NULL
were	NULL
both	NULL
inhibited	NULL
by	NULL
the	NULL
-236	NULL
to	NULL
-215	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
consensus	NULL
J-	NULL
and	NULL
AML1-binding	NULL
sites	NULL
.	NULL

Two	NULL
separate	NULL
trinucleotide	NULL
mutations	NULL
within	NULL
this	NULL
oligonucleotide	NULL
at	NULL
the	NULL
Jk	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-236/-215A3	NULL
and	NULL
-236/-215Â¥4	NULL
)	NULL
disrupted	NULL
competition	NULL
of	NULL
the	NULL
putative	NULL
Jk	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
5	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
putative	NULL
Jx	NULL
complex	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
a	NULL
site	NULL
derived	NULL
from	NULL
the	NULL
EBV	NULL
LMP2A	NULL
EZ2RE	NULL
(	NULL
16	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
preincubation	NULL
of	NULL
extract	NULL
with	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
fusion	NULL
protein	NULL
resin	NULL
(	NULL
48	NULL
)	NULL
efficiently	NULL
depleted	NULL
the	NULL
putative	NULL
Jk-binding	NULL
activity	NULL
from	NULL
nuclear	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
this	NULL
complex	NULL
is	NULL
due	NULL
to	NULL
Jk	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
-236	NULL
to	NULL
-215	NULL
oligonucleotide	NULL
within	NULL
the	NULL
consensus	NULL
AML1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-236/-215A1	NULL
and	NULL
-236/-215A2	NULL
)	NULL
disrupted	NULL
competition	NULL
for	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
EBNA-2	NULL
TRANSACTIVATION	NULL
OF	NULL
LMP-1	NULL
257	NULL
C	NULL
3	NULL
-	NULL
op	NULL
-	NULL
4	NULL
4	NULL
_	NULL
4	NULL
4	NULL
$	NULL
2	NULL
8	NULL
88	NULL
Â§	NULL
8	NULL
Â§	NULL
*	NULL
$	NULL
9	NULL
4	NULL
gg	NULL
a	NULL
a	NULL
a	NULL
ga	NULL
Q	NULL
a	NULL
=	NULL
-	NULL
3	NULL
3	NULL
Â§	NULL
%	NULL
yon	NULL
a	NULL
Â©	NULL
g	NULL
or	NULL
cw	NULL
a	NULL
)	NULL
Z	NULL
Z	NULL
a	NULL
c	NULL
â¬	NULL
om	NULL
o	NULL
Â®	NULL
m	NULL
m	NULL
#	NULL
N	NULL
-	NULL
-	NULL
3	NULL
38	NULL
5	NULL
2	NULL
â¬	NULL
$	NULL
m	NULL
V	NULL
a	NULL
y	NULL
q	NULL
a	NULL
a	NULL
a	NULL
&	NULL
3	NULL
$	NULL
Ã©mgqlâpqlql	NULL
A	NULL
Z	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
7	NULL
9	NULL
P	NULL
A	NULL
Z	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
n	NULL
if	NULL
'	NULL
-LBF6	NULL
M	NULL
BHâLBF6	NULL
Ili'nll	NULL
'	NULL
LBFS	NULL
d	NULL
-	NULL
ba	NULL
i-bs	NULL
-LBFS	NULL
_	NULL
AML1ss	NULL
u	NULL
Ha	NULL
â	NULL
but	NULL
-LBF3	NULL
QHHHHHHH	NULL
-LBF3	NULL
H	NULL
*	NULL
-LBFi	NULL
%	NULL
n	NULL
-LBFI/AML1	NULL
-Jx	NULL
-I	NULL
wet	NULL
_LBF	NULL
â	NULL
7	NULL
Â®	NULL
_LBF7	NULL
-P	NULL
-p	NULL
-P	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
10	NULL
2	NULL
03	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
1	NULL
2	NULL
3	NULL
g	NULL
LBF	NULL
5/6	NULL
-236	NULL
|	NULL
<	NULL
Ix	NULL
LBF7	NULL
-190	NULL
_	NULL
-145	NULL
BINDING	NULL
CTTGGCJACCGCNITCCCACAGCTMIGCCCCCCGSECACCCECTTITC~~~~ACATG	NULL
Jk	NULL
AMLLl	NULL
LBF3	NULL
LBFS5/6	NULL
LBF7	NULL
-ese/-145	NULL
++	NULL
++	NULL
++	NULL
++	NULL
++	NULL
~215/-145	NULL
=	NULL
-	NULL
+	NULL
-	NULL
+	NULL
~187/-145	NULL
-	NULL
-	NULL
-	NULL
-	NULL
~215/-174	NULL
-	NULL
+/-	NULL
+	NULL
-	NULL
++	NULL
-236/-196	NULL
.	NULL

++	NULL
++	NULL
+	NULL
++	NULL
++	NULL
-236/-215	NULL
.	NULL

++	NULL
++	NULL
-	NULL
-	NULL
-236/-215A1	NULL
++	NULL
=	NULL
~236/-21542	NULL
++	NULL
-236/-21503	NULL
-	NULL
++	NULL
~236/-21544	NULL
.	NULL

-	NULL
++	NULL
-227/-203	NULL
.	NULL

+	NULL
+++	NULL
-	NULL
+	NULL
++	NULL
-	NULL
-	NULL
-	NULL
++	NULL
-227/-20302	NULL
.	NULL

+	NULL
++	NULL
+	NULL
_	NULL
-215/-192	NULL
-	NULL
-	NULL
-	NULL
-	NULL
++	NULL
-215/-192A1	NULL
-215/-19282	NULL
-215/-19203	NULL
2157-1924	NULL
~215/-19205	NULL
++	NULL
AMTAGG-	NULL
-215/-19286	NULL
++	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
facilitates	NULL
detection	NULL
of	NULL
other	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
a	NULL
-236/-145	NULL
LMP-1	NULL
E2RE	NULL
,	NULL
including	NULL
Jx	NULL
and	NULL
AMLA	NULL
.	NULL

EMSA	NULL
analysis	NULL
of	NULL
B-cell	NULL
extract	NULL
with	NULL
a	NULL
-236/-145	NULL
LMP-1	NULL
probe	NULL
mutated	NULL
at	NULL
the	NULL
PU.1	NULL
site	NULL
(	NULL
same	NULL
mutation	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
-168/-145A1	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Six	NULL
EMSA	NULL
complexes	NULL
are	NULL
evident	NULL
and	NULL
are	NULL
labeled	NULL
LBF1	NULL
,	NULL
LBF3	NULL
,	NULL
LBF3	NULL
,	NULL
LBF6	NULL
,	NULL
LBF7	NULL
,	NULL
and	NULL
Jx	NULL
.	NULL

Overlapping	NULL
competitor	NULL
oligonucleotides	NULL
(	NULL
described	NULL
below	NULL
in	NULL
panel	NULL
D	NULL
)	NULL
were	NULL
used	NULL
to	NULL
localize	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
each	NULL
factor	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Binding	NULL
sites	NULL
for	NULL
each	NULL
factor	NULL
were	NULL
further	NULL
defined	NULL
by	NULL
mutated	NULL
competitor	NULL
oligonucleotides	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
LBF	NULL
]	NULL
complex	NULL
is	NULL
supershifted	NULL
by	NULL
AML1	NULL
antibody	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
not	NULL
by	NULL
control	NULL
antibody	NULL
to	NULL
PU.1	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
supershifted	NULL
complex	NULL
(	NULL
ss	NULL
)	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
specific	NULL
AML1-binding-site	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
AML1	NULL
oligonucleotide	NULL
sequence	NULL
was	NULL
GGATATTTGCGGTTAGCA	NULL
(	NULL
47	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Summary	NULL
of	NULL
wild-type	NULL
and	NULL
mutated	NULL
oligonucleotide	NULL
competitors	NULL
used	NULL
to	NULL
localize	NULL
LBFI/AML1-	NULL
,	NULL
LBF3-	NULL
,	NULL
LBFS-	NULL
,	NULL
LBF6-	NULL
,	NULL
LBF7-	NULL
,	NULL
and	NULL
Jx-binding	NULL
sites	NULL
.	NULL

Oligonucleotides	NULL
are	NULL
described	NULL
at	NULL
left	NULL
.	NULL

=	NULL
,	NULL
native	NULL
sequence	NULL
.	NULL

Mutated	NULL
bases	NULL
are	NULL
listed	NULL
.	NULL

+/-	NULL
,	NULL
barely	NULL
detectable	NULL
competition	NULL
.	NULL

LBF5	NULL
and	NULL
LBF6	NULL
are	NULL
grouped	NULL
together	NULL
because	NULL
the	NULL
results	NULL
were	NULL
identical	NULL
for	NULL
each	NULL
competitor	NULL
sequence	NULL
.	NULL

*	NULL
,	NULL
the	NULL
-227	NULL
to	NULL
-203	NULL
oligonucleotide	NULL
inhibited	NULL
the	NULL
AML1	NULL
complex	NULL
because	NULL
of	NULL
a	NULL
5-	NULL
of	NULL
6-bp	NULL
match	NULL
to	NULL
the	NULL
consensus	NULL
AML1	NULL
site	NULL
(	NULL
30	NULL
)	NULL
in	NULL
this	NULL
oligonucleotide	NULL
.	NULL

the	NULL
LBF1	NULL
complex	NULL
but	NULL
not	NULL
the	NULL
Jx	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
4	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
LBF1	NULL
as	NULL
AML1	NULL
was	NULL
confirmed	NULL
by	NULL
incubation	NULL
of	NULL
nuclear	NULL
extract	NULL
with	NULL
anti-AML1	NULL
antibody	NULL
prior	NULL
to	NULL
EMSA	NULL
.	NULL

Anti-AML1	NULL
but	NULL
not	NULL
control	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
1	NULL
,	NULL
respectively	NULL
)	NULL
resulted	NULL
in	NULL
an	NULL
additional	NULL
supershifted	NULL
complex	NULL
and	NULL
partial	NULL
depletion	NULL
of	NULL
the	NULL
LBF1	NULL
complex	NULL
,	NULL
confirming	NULL
that	NULL
LBF1	NULL
is	NULL
AML1	NULL
.	NULL

The	NULL
supershifted	NULL
AML1	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
CBFa	NULL
Â«	NULL
(	NULL
murine	NULL
AML1	NULL
}	NULL
)	NULL
-binding	NULL
site	NULL
(	NULL
47	NULL
)	NULL
that	NULL
is	NULL
also	NULL
recognized	NULL
by	NULL
human	NULL
AML1	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
AML1	NULL
,	NULL
LBFS5	NULL
,	NULL
and	NULL
LBF6	NULL
complexes	NULL
were	NULL
all	NULL
partially	NULL
inhibited	NULL
by	NULL
a	NULL
-227	NULL
to	NULL
-203	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Competition	NULL
for	NULL
the	NULL
AML1	NULL
complex	NULL
was	NULL
unexpected	NULL
with	NULL
-227	NULL
to	NULL
-203	NULL
,	NULL
since	NULL
it	NULL
does	NULL
not	NULL
include	NULL
the	NULL
entire	NULL
AML1	NULL
consensus	NULL
.	NULL

Inspection	NULL
of	NULL
the	NULL
-227	NULL
to	NULL
-203	NULL
sequence	NULL
,	NULL
however	NULL
,	NULL
revealed	NULL
a	NULL
degenerate	NULL
(	NULL
5-	NULL
of	NULL
6-bp	NULL
match	NULL
)	NULL
AML1	NULL
site	NULL
,	NULL
TGT	NULL
GGG	NULL
,	NULL
at	NULL
-220	NULL
to	NULL
-216	NULL
(	NULL
within	NULL
the	NULL
Jx	NULL
consensus	NULL
[	NULL
Fig	NULL
.	NULL

SDJ	NULL
)	NULL
.	NULL

Mutation	NULL
within	NULL
this	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-227/-203A1	NULL
)	NULL
completely	NULL
disrupted	NULL
AML1	NULL
inhibition	NULL
by	NULL
this	NULL
oligonucleotide	NULL
.	NULL

In	NULL
the	NULL
context	NULL
of	NULL
the	NULL
native	NULL
LMP-1	NULL
promoter	NULL
sequence	NULL
,	NULL
this	NULL
degenerate	NULL
AML1	NULL
site	NULL
within	NULL
the	NULL
Jx	NULL
site	NULL
does	NULL
not	NULL
have	NULL
significant	NULL
binding	NULL
activity	NULL
,	NULL
since	NULL
the	NULL
-236	NULL
to	NULL
-215	NULL
oligonucleotide	NULL
which	NULL
includes	NULL
both	NULL
the	NULL
consensus	NULL
AML1	NULL
site	NULL
at	NULL
-224	NULL
to	NULL
-229	NULL
and	NULL
the	NULL
degenerate	NULL
site	NULL
at	NULL
-220	NULL
to	NULL
-216	NULL
does	NULL
not	NULL
bind	NULL
any	NULL
AML1	NULL
258	NULL
JOHANNSEN	NULL
ET	NULL
AL	NULL
.	NULL

when	NULL
the	NULL
consensus	NULL
site	NULL
is	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
-227	NULL
to	NULL
=-203	NULL
oligonucleotide	NULL
at	NULL
-211	NULL
to	NULL
-215	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-227/-203AÂ¥1	NULL
)	NULL
also	NULL
disrupted	NULL
the	NULL
partial	NULL
inhibition	NULL
of	NULL
LBFS	NULL
and	NULL
LBF6	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
whereas	NULL
an	NULL
adjacent	NULL
pentanucle-otide	NULL
mutation	NULL
at	NULL
-208	NULL
to	NULL
-204	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-227/-203A2	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
competitor	NULL
activity	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
mutation	NULL
of	NULL
nucleotides	NULL
-208	NULL
to	NULL
-204	NULL
did	NULL
not	NULL
ablate	NULL
competition	NULL
by	NULL
the	NULL
-227/-203A2	NULL
oligonucleotide	NULL
,	NULL
the	NULL
LBFS-	NULL
and	NULL
LBF6-binding	NULL
site	NULL
(	NULL
s	NULL
)	NULL
must	NULL
lie	NULL
between	NULL
-227	NULL
and	NULL
-209	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

The	NULL
LBF7	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
both	NULL
the	NULL
-227	NULL
to	NULL
-203	NULL
and	NULL
-215	NULL
to	NULL
-192	NULL
overlapping	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
,	NULL
thus	NULL
narrowing	NULL
its	NULL
binding	NULL
site	NULL
to	NULL
within	NULL
13	NULL
bp	NULL
(	NULL
-215	NULL
to	NULL
-203	NULL
)	NULL
.	NULL

An	NULL
array	NULL
of	NULL
mutations	NULL
placed	NULL
within	NULL
both	NULL
of	NULL
these	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
allowed	NULL
further	NULL
localization	NULL
of	NULL
LBF7	NULL
.	NULL

Five	NULL
separate	NULL
mutations	NULL
that	NULL
fell	NULL
within	NULL
the	NULL
-211	NULL
to	NULL
-203	NULL
sequence	NULL
GCCCCCCGG	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-215/-192A1	NULL
,	NULL
-215/-192A2	NULL
,	NULL
-215/-192A3	NULL
,	NULL
-215/-192M44	NULL
,	NULL
and	NULL
-227	NULL
-203A2	NULL
)	NULL
disrupted	NULL
LBF7	NULL
competition	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
9	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
whereas	NULL
three	NULL
mutations	NULL
that	NULL
bracket	NULL
this	NULL
sequence	NULL
on	NULL
either	NULL
end	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-227/-203A1	NULL
,	NULL
-215/	NULL
-192A5	NULL
,	NULL
and	NULL
-215/-192A6	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
LBF7	NULL
competition	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
7	NULL
,	NULL
and	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
thus	NULL
map	NULL
the	NULL
LBF7	NULL
recognition	NULL
site	NULL
to	NULL
the	NULL
sequence	NULL
GCCCCCCGG	NULL
.	NULL

The	NULL
LBF3-binding	NULL
site	NULL
was	NULL
less	NULL
precisely	NULL
mapped	NULL
.	NULL

LBF3	NULL
was	NULL
inhibited	NULL
by	NULL
unlabeled	NULL
-236/-145APU.1	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
partially	NULL
inhibited	NULL
by	NULL
the	NULL
-215/-145	NULL
,	NULL
-215/-174	NULL
,	NULL
and	NULL
-236/-196	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
smaller	NULL
overlapping	NULL
22-bp	NULL
oligonucleotides	NULL
derived	NULL
from	NULL
this	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-236/-215	NULL
,	NULL
-227/-203	NULL
,	NULL
and	NULL
-215/-192	NULL
)	NULL
failed	NULL
to	NULL
compete	NULL
for	NULL
LBF3	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
the	NULL
core	NULL
of	NULL
the	NULL
LBF3-binding	NULL
site	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
within	NULL
the	NULL
sequence	NULL
from	NULL
-215	NULL
to	NULL
-196	NULL
and	NULL
that	NULL
additional	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
sequences	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
binding	NULL
.	NULL

Mutation	NULL
of	NULL
residues	NULL
-208	NULL
to	NULL
-201	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
full-length	NULL
-236	NULL
to	NULL
-145	NULL
E2RE	NULL
oligonucleotide	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
-215/-192A1	NULL
,	NULL
for	NULL
mutation	NULL
)	NULL
,	NULL
however	NULL
,	NULL
did	NULL
not	NULL
eliminate	NULL
its	NULL
ability	NULL
to	NULL
compete	NULL
for	NULL
LBF3	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
core	NULL
of	NULL
the	NULL
LBF3-binding	NULL
site	NULL
is	NULL
between	NULL
-215	NULL
and	NULL
-196	NULL
,	NULL
and	NULL
nucleotides	NULL
-208	NULL
through	NULL
-201	NULL
are	NULL
not	NULL
critical	NULL
for	NULL
sequence-specific	NULL
binding	NULL
.	NULL

Lymphocytes	NULL
and	NULL
epithelial	NULL
cells	NULL
express	NULL
different	NULL
nuclear	NULL
factors	NULL
that	NULL
recognize	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
is	NULL
readily	NULL
demonstrable	NULL
in	NULL
B	NULL
lymphocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
lymphocytes	NULL
or	NULL
epithelial	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
46	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
factors	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
LMP-1	NULL
EZRE	NULL
cell	NULL
type	NULL
specificity	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
various	NULL
epithelial	NULL
and	NULL
B-lymphocyte	NULL
cell	NULL
lines	NULL
,	NULL
using	NULL
the	NULL
-236/	NULL
-145	NULL
and	NULL
-236/-145APU.1	NULL
LMP	NULL
probes	NULL
.	NULL

EBV-positive	NULL
cell	NULL
lines	NULL
were	NULL
also	NULL
tested	NULL
to	NULL
ascertain	NULL
whether	NULL
any	NULL
LMP-1	NULL
EZRE-binding	NULL
factors	NULL
are	NULL
modulated	NULL
by	NULL
EBV	NULL
latent-gene	NULL
expression	NULL
.	NULL

Figure	NULL
6A	NULL
demonstrates	NULL
that	NULL
Jx	NULL
was	NULL
present	NULL
in	NULL
B	NULL
,	NULL
T	NULL
,	NULL
and	NULL
epithelial	NULL
cells	NULL
while	NULL
PU.1	NULL
expression	NULL
was	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
previously	NULL
reported	NULL
distribution	NULL
of	NULL
these	NULL
factors	NULL
(	NULL
17	NULL
,	NULL
22	NULL
)	NULL
.	NULL

LBF3	NULL
,	NULL
LBF5	NULL
,	NULL
and	NULL
LBF7	NULL
were	NULL
also	NULL
expressed	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

LBF4	NULL
was	NULL
present	NULL
in	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
but	NULL
absent	NULL
from	NULL
epithelial	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

LBF1/	NULL
AML1	NULL
was	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
and	NULL
was	NULL
upregulated	NULL
in	NULL
EBV-positive	NULL
B-cell	NULL
lines	NULL
,	NULL
except	NULL
in	NULL
the	NULL
BL41	NULL
cell	NULL
line	NULL
infected	NULL
with	NULL
the	NULL
defective	NULL
P3HR1	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

P3HR1	NULL
virus	NULL
expresses	NULL
only	NULL
EBNA-1	NULL
,	NULL
EBNA-3A	NULL
,	NULL
EBNA-3B	NULL
,	NULL
and	NULL
EBNA-3C	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
.	NULL

A	NULL
novel	NULL
complex	NULL
,	NULL
LBF2	NULL
,	NULL
was	NULL
noted	NULL
only	NULL
in	NULL
epithelial	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
and	NULL
was	NULL
localized	NULL
by	NULL
competition	NULL
experiments	NULL
to	NULL
the	NULL
LBF7-binding	NULL
region	NULL
between	NULL
-215	NULL
and	NULL
-192	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

EBV	NULL
positive	NULL
B	NULL
cell	NULL
lines	NULL
EBV	NULL
negative	NULL
B	NULL
cell	NULL
lines	NULL
Epithelial	NULL
cell	NULL
lines	NULL
BL41/P3HR	NULL
1	NULL
BL41/B95-8	NULL
Jijpoye	NULL
Louckes	NULL
Lou/EBNA2	NULL
Jurkat	NULL
293	NULL
HeLa	NULL
$	NULL
4	NULL
5	NULL
â¬	NULL
i	NULL
t	NULL
a.	NULL
m	NULL
Raji	NULL
IB4	NULL
jul	NULL
bet	NULL
-	NULL
|	NULL
|	NULL
W	NULL
49	NULL
_	NULL
;	NULL
;	NULL
;	NULL
;	NULL
;	NULL
--	NULL
--	NULL
PUJ	NULL
-J	NULL
RSBP	NULL
~-	NULL
-236/-145	NULL
EBV	NULL
positive	NULL
B	NULL
cell	NULL
lines	NULL
9	NULL
>	NULL
'	NULL
B	NULL
w	NULL
<	NULL
o	NULL
5D	NULL
A	NULL
a	NULL
:	NULL
S	NULL
ï¬â	NULL
u	NULL
a	NULL
8	NULL
E4	NULL
mn	NULL
Epithelial	NULL
cell	NULL
lines	NULL
|	NULL
}	NULL
Lou/EBNA2	NULL
BIA1/P3HR	NULL
I	NULL
BL41/B95-8	NULL
Jijoye	NULL
probe	NULL
BJAB	NULL
Louckes	NULL
Raji	NULL
1B4	NULL
Jurkat	NULL
293	NULL
HeLa	NULL
d	NULL
*	NULL
-LBF6	NULL
.	NULL

Ls	NULL
I	NULL
-Jx	NULL
fest	NULL
j	NULL
-LBE7	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

B	NULL
,	NULL
T	NULL
,	NULL
and	NULL
epithelial	NULL
cells	NULL
have	NULL
distinct	NULL
factors	NULL
that	NULL
recognize	NULL
the	NULL
minimal	NULL
E2RE	NULL
.	NULL

EMSAs	NULL
with	NULL
-236/-145	NULL
probe	NULL
(	NULL
A	NULL
)	NULL
or	NULL
-236/-145APU.1	NULL
probe	NULL
(	NULL
B	NULL
)	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
various	NULL
cell	NULL
lines	NULL
.	NULL

BL41	NULL
and	NULL
Louckes	NULL
are	NULL
EBV-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Lou/EBNAZ	NULL
is	NULL
a	NULL
Louckes	NULL
cell	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
an	NULL
EBNA-2	NULL
expression	NULL
vector	NULL
(	NULL
45	NULL
)	NULL
.	NULL

BL41/P3HR1	NULL
and	NULL
BL41/B95-8	NULL
are	NULL
EBV-infected	NULL
BL41	NULL
cell	NULL
lines	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Jijoye	NULL
and	NULL
Raji	NULL
are	NULL
EBV-infected	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
IB4	NULL
is	NULL
an	NULL
EBV-transformed	NULL
cell	NULL
line	NULL
.	NULL

Jurkat	NULL
is	NULL
a	NULL
T-cell	NULL
line	NULL
.	NULL

293	NULL
and	NULL
HeLa	NULL
are	NULL
kidney	NULL
and	NULL
cervical	NULL
epithelial-cell	NULL
lines	NULL
,	NULL
respectively	NULL
.	NULL

Complexes	NULL
identified	NULL
by	NULL
competition	NULL
experiments	NULL
are	NULL
listed	NULL
to	NULL
the	NULL
right	NULL
.	NULL

The	NULL
AML1	NULL
complex	NULL
is	NULL
upregulated	NULL
in	NULL
the	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
except	NULL
in	NULL
the	NULL
BL41	NULL
cell	NULL
line	NULL
infected	NULL
with	NULL
the	NULL
defective	NULL
P3HR1	NULL
virus	NULL
that	NULL
expresses	NULL
only	NULL
the	NULL
EBNA-1	NULL
,	NULL
EBNA-3A	NULL
,	NULL
EBNA-3B	NULL
,	NULL
and	NULL
EBNA-3C	NULL
EBV	NULL
gene	NULL
products	NULL
.	NULL

-LBFS	NULL
b	NULL
4	NULL
nââLBF2	NULL
LBF3	NULL
--	NULL
--	NULL
LBFI	NULL
(	NULL
AML1	NULL
)	NULL
PU.1	NULL
is	NULL
critical	NULL
for	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
the	NULL
LMP-1	NULL
upstream	NULL
region	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
contribution	NULL
of	NULL
LMP-1	NULL
EZRE-binding	NULL
factors	NULL
to	NULL
EBNA-2	NULL
transactivation	NULL
,	NULL
trinucleotide	NULL
mutations	NULL
that	NULL
disrupted	NULL
the	NULL
binding	NULL
of	NULL
LBFI/AML1I	NULL
,	NULL
Jx	NULL
,	NULL
PU.1+LBF4	NULL
,	NULL
or	NULL
LBF4	NULL
alone	NULL
were	NULL
introduced	NULL
into	NULL
LMP-1	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
Fold	NULL
Activation	NULL
140	NULL
0	NULL
_n	NULL
s	NULL
o	NULL
a	NULL
3	NULL
n	NULL
Fold	NULL
Activation	NULL
-a	NULL
ro	NULL
w	NULL
a	NULL
&	NULL
n	NULL
-236	NULL
[	NULL
--	NULL
--	NULL
-|	NULL
-145	NULL
-236	NULL
|-AJx	NULL
--	NULL
-	NULL
-145	NULL
-236	NULL
|	NULL
--	NULL
APU.1	NULL
{	NULL
-145	NULL
-215	NULL
[	NULL
--	NULL
-	NULL
145	NULL
215	NULL
[	NULL
-APU.11	NULL
-145	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
AML1-	NULL
,	NULL
Jx-	NULL
,	NULL
and	NULL
PU.1-binding	NULL
sites	NULL
indicate	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
these	NULL
factors	NULL
in	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

EBNA-2-induced	NULL
increases	NULL
in	NULL
CAT	NULL
activity	NULL
from	NULL
LMP1	NULL
promoter	NULL
CAT	NULL
reporter	NULL
plasmids	NULL
or	NULL
from	NULL
LMP1	NULL
promoter	NULL
upstream	NULL
elements	NULL
positioned	NULL
upstream	NULL
of	NULL
the	NULL
HSV	NULL
TK	NULL
promoter	NULL
and	NULL
CAT	NULL
reporter	NULL
are	NULL
indicated	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
deviation	NULL
of	NULL
values	NULL
in	NULL
independent	NULL
assays	NULL
.	NULL

promoter-CAT	NULL
constructs	NULL
.	NULL

Mutation	NULL
of	NULL
nucleotides	NULL
-211	NULL
to	NULL
-213	NULL
disrupted	NULL
the	NULL
binding	NULL
of	NULL
Jx	NULL
and	NULL
reduced	NULL
the	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
p-236/LMP	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
or	NULL
pTK-236/	NULL
-145	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
constructs	NULL
from	NULL
10-	NULL
to	NULL
3.2-fold	NULL
or	NULL
from	NULL
4.7-	NULL
to	NULL
2.0-fold	NULL
,	NULL
respectively	NULL
.	NULL

Mutation	NULL
of	NULL
nucleotides	NULL
-230	NULL
to	NULL
-228	NULL
disrupted	NULL
LBF1/AML1	NULL
binding	NULL
and	NULL
had	NULL
a	NULL
small	NULL
effect	NULL
on	NULL
the	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
p-236/LMP	NULL
in	NULL
the	NULL
one	NULL
experiment	NULL
shown	NULL
for	NULL
this	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
the	NULL
AML1l-binding-site	NULL
mutant	NULL
had	NULL
slightly	NULL
greater	NULL
EBNA-2	NULL
responsiveness	NULL
than	NULL
did	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
AML1	NULL
binding	NULL
is	NULL
not	NULL
required	NULL
for	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

The	NULL
LBFA4	NULL
mutation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
-176/-151A1	NULL
)	NULL
also	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
-236/LMP	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
participation	NULL
of	NULL
LBF4	NULL
in	NULL
EZRE	NULL
activity	NULL
,	NULL
since	NULL
this	NULL
mutation	NULL
only	NULL
partially	NULL
disrupts	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Disruption	NULL
of	NULL
both	NULL
PU.1	NULL
and	NULL
LBF4	NULL
binding	NULL
with	NULL
the	NULL
-166	NULL
to	NULL
-164	NULL
mutation	NULL
surprisingly	NULL
abolished	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
LMP-1	NULL
EZRE	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
p-236/LMP	NULL
,	NULL
p-215/LMP	NULL
,	NULL
and	NULL
pTK-236/-145	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PU.1	NULL
(	NULL
or	NULL
,	NULL
less	NULL
probably	NULL
,	NULL
LBF4	NULL
)	NULL
is	NULL
an	NULL
essential	NULL
mediator	NULL
of	NULL
LMP-1	NULL
EBNA-2	NULL
transactivation	NULL
,	NULL
while	NULL
Jx	NULL
is	NULL
critical	NULL
for	NULL
full	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

GST-EBNA-2	NULL
fusion	NULL
protein	NULL
interacts	NULL
directly	NULL
with	NULL
PU.1	NULL
.	NULL

The	NULL
dramatic	NULL
effect	NULL
of	NULL
the	NULL
PU.1	NULL
mutation	NULL
on	NULL
EBNA-2	NULL
responsiveness	NULL
could	NULL
be	NULL
due	NULL
to	NULL
a	NULL
direct	NULL
interaction	NULL
between	NULL
EBNA-2	NULL
and	NULL
PU.1	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
a	NULL
GST-EBNA-2	NULL
fusion	NULL
protein	NULL
containing	NULL
EBNA-2	NULL
residues	NULL
310	NULL
to	NULL
376	NULL
[	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
(	NULL
48	NULL
)	NULL
]	NULL
bound	NULL
to	NULL
glutathione-Sepharose	NULL
was	NULL
incubated	NULL
with	NULL
either	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
or	NULL
*Â°S-labeled	NULL
in	NULL
vitro	NULL
EBNA-2	NULL
TRANSACTIVATION	NULL
OF	NULL
LMP-1	NULL
259	NULL
A	NULL
B	NULL
bul	NULL
b=l	NULL
bt	NULL
-LBF4	NULL
U	NULL
-	NULL
â	NULL
-PU.1	NULL
79-	NULL
50Â°	NULL
se	NULL
-	NULL
--	NULL
-PU.j	NULL
85-	NULL
n	NULL
ï¬-probe	NULL
3	NULL
1	NULL
2	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

EBNA-2	NULL
interacts	NULL
directly	NULL
with	NULL
PU.1	NULL
.	NULL

Purified	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
protein	NULL
can	NULL
bind	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
(	NULL
A	NULL
)	NULL
or	NULL
can	NULL
deplete	NULL
PU.1	NULL
from	NULL
crude	NULL
nuclear	NULL
extract	NULL
(	NULL
B	NULL
)	NULL
.	NULL

S-labeled	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
glutathione	NULL
Sepharose-bound	NULL
GST	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
After	NULL
being	NULL
washed	NULL
,	NULL
the	NULL
beads	NULL
were	NULL
eluted	NULL
in	NULL
sample	NULL
buffer	NULL
and	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
reticulocyte	NULL
lysate	NULL
in	NULL
lane	NULL
1	NULL
is	NULL
one-third	NULL
of	NULL
that	NULL
used	NULL
in	NULL
the	NULL
experiments	NULL
for	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
45-kDa	NULL
PU.1	NULL
polypeptide	NULL
is	NULL
indicated	NULL
.	NULL

In	NULL
panel	NULL
B	NULL
,	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
was	NULL
incubated	NULL
twice	NULL
for	NULL
30	NULL
min	NULL
each	NULL
with	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
with	NULL
GST-EBNA-2	NULL
(	NULL
310-337	NULL
)	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
EMSA	NULL
with	NULL
a	NULL
-236/-145	NULL
probe	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
PU.1	NULL
and	NULL
LBF4	NULL
EMSA	NULL
complexes	NULL
are	NULL
indicated	NULL
.	NULL

translated	NULL
PU.1	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
,	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
(	NULL
48	NULL
)	NULL
adsorbed	NULL
about	NULL
30	NULL
%	NULL
of	NULL
*Â°S-labeled	NULL
recombinant	NULL
PU.1	NULL
protein	NULL
whereas	NULL
GST	NULL
absorbed	NULL
little	NULL
or	NULL
no	NULL
PU.1	NULL
.	NULL

The	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
fusion	NULL
protein	NULL
also	NULL
extensively	NULL
depleted	NULL
PU.1	NULL
EMSA	NULL
activity	NULL
from	NULL
B-cell	NULL
nuclear	NULL
ex-tracts	NULL
,	NULL
whereas	NULL
a	NULL
smaller	NULL
protein	NULL
,	NULL
GST-EBNA-2	NULL
(	NULL
310-337	NULL
)	NULL
,	NULL
had	NULL
little	NULL
effect	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
EBNA-2	NULL
domain	NULL
from	NULL
amino	NULL
acids	NULL
310	NULL
to	NULL
376	NULL
can	NULL
interact	NULL
with	NULL
recombinant	NULL
PU.1	NULL
and	NULL
can	NULL
specifically	NULL
deplete	NULL
native	NULL
PU.1	NULL
from	NULL
nuclear	NULL
extracts	NULL
.	NULL

As	NULL
a	NULL
further	NULL
internal	NULL
control	NULL
,	NULL
LBF4	NULL
,	NULL
which	NULL
also	NULL
binds	NULL
to	NULL
the	NULL
-236	NULL
to	NULL
-145	NULL
probe	NULL
,	NULL
was	NULL
not	NULL
depleted	NULL
by	NULL
incubation	NULL
with	NULL
GST-EBNA-2	NULL
(	NULL
310-376	NULL
)	NULL
protein	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

An	NULL
attempt	NULL
to	NULL
immunoprecipitate	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
full-length	NULL
EBNA-2	NULL
and	NULL
an	NULL
EBNA-2	NULL
monoclonal	NULL
antibody	NULL
(	NULL
PEZ	NULL
[	NULL
49	NULL
]	NULL
)	NULL
was	NULL
unsuccessful	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
much	NULL
smaller	NULL
amount	NULL
of	NULL
EBNA-2	NULL
used	NULL
in	NULL
this	NULL
experiment	NULL
(	NULL
at	NULL
least	NULL
100-fold	NULL
less	NULL
than	NULL
in	NULL
the	NULL
GST-EBNA-2	NULL
experiment	NULL
)	NULL
.	NULL

DISCUSSION	NULL
These	NULL
and	NULL
previous	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
EBV	NULL
LMP-1	NULL
promoter	NULL
is	NULL
dependent	NULL
for	NULL
its	NULL
activation	NULL
on	NULL
the	NULL
interaction	NULL
of	NULL
EBNA-2	NULL
with	NULL
both	NULL
ubiquitous	NULL
and	NULL
tissue-specific	NULL
host	NULL
cell	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Binding-site	NULL
mutational	NULL
analysis	NULL
showed	NULL
that	NULL
EBNA-2	NULL
activation	NULL
of	NULL
the	NULL
LMP-1	NULL
promoter	NULL
in	NULL
B	NULL
cells	NULL
is	NULL
partially	NULL
dependent	NULL
on	NULL
interaction	NULL
with	NULL
the	NULL
ubiquitous	NULL
Jx	NULL
protein	NULL
and	NULL
is	NULL
completely	NULL
dependent	NULL
on	NULL
interaction	NULL
with	NULL
the	NULL
B-lymphocyte-	NULL
,	NULL
macrophage-	NULL
,	NULL
and	NULL
erythropoietic-cell-specific	NULL
PU.1	NULL
protein	NULL
.	NULL

At	NULL
least	NULL
six	NULL
other	NULL
B-cell	NULL
proteins	NULL
bind	NULL
to	NULL
a	NULL
-236	NULL
to	NULL
-145	NULL
LMP-1	NULL
minimal	NULL
EZRE	NULL
and	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
EBNA-2	NULL
responsiveness	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
the	NULL
AML1-	NULL
and	NULL
LBF4-binding	NULL
sites	NULL
have	NULL
been	NULL
specifically	NULL
mutated	NULL
,	NULL
and	NULL
these	NULL
binding	NULL
sites	NULL
appear	NULL
not	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

Since	NULL
a	NULL
-215	NULL
LMP-1	NULL
promoter	NULL
construct	NULL
is	NULL
partially	NULL
EBNA-2	NULL
responsive	NULL
,	NULL
whereas	NULL
a	NULL
-205	NULL
construct	NULL
is	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
41	NULL
)	NULL
,	NULL
a	NULL
factor	NULL
which	NULL
interacts	NULL
with	NULL
-215	NULL
to	NULL
-205	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
important	NULL
for	NULL
EBNA-2	NULL
response	NULL
.	NULL

LBF3	NULL
,	NULL
LBF5	NULL
,	NULL
LBF6	NULL
,	NULL
or	NULL
LBF7	NULL
map	NULL
within	NULL
or	NULL
near	NULL
this	NULL
critical	NULL
-215	NULL
to	NULL
-205	NULL
site	NULL
and	NULL
may	NULL
therefore	NULL
mediate	NULL
this	NULL
effect	NULL
.	NULL

LBF3	NULL
and	NULL
LBF7	NULL
bind	NULL
to	NULL
a	NULL
-215/-145	NULL
probe	NULL
,	NULL
while	NULL
LBF5	NULL
and	NULL
LBF6	NULL
require	NULL
additional	NULL
upstream	NULL
sequence	NULL
,	NULL
which	NULL
could	NULL
be	NULL
sequence	NULL
nonspecific	NULL
and	NULL
260	NULL
JOHANNSEN	NULL
ET	NULL
AL	NULL
.	NULL

cidic	NULL
omain	NULL
(	NULL
]	NULL
-200	NULL
LMP-1	NULL
Promoter	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Model	NULL
of	NULL
EBNA-2	NULL
interactions	NULL
with	NULL
E2RE-binding	NULL
factors	NULL
and	NULL
basal	NULL
transcription	NULL
factors	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

EBNA-2	NULL
is	NULL
an	NULL
acidic	NULL
transcriptional	NULL
transactivator	NULL
which	NULL
requires	NULL
sequence-specific	NULL
DNA-binding	NULL
proteins	NULL
to	NULL
direct	NULL
it	NULL
to	NULL
response	NULL
elements	NULL
.	NULL

The	NULL
EBNA-2	NULL
acidic	NULL
domain	NULL
can	NULL
interact	NULL
with	NULL
TFIIB	NULL
,	NULL
TAF40	NULL
,	NULL
and	NULL
TFIIH	NULL
in	NULL
stimulating	NULL
transcription	NULL
.	NULL

Whether	NULL
it	NULL
does	NULL
so	NULL
sequentially	NULL
or	NULL
as	NULL
a	NULL
complex	NULL
of	NULL
more	NULL
than	NULL
one	NULL
EBNA-2	NULL
molecule	NULL
interacting	NULL
simultaneously	NULL
with	NULL
more	NULL
than	NULL
one	NULL
factor	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Jx	NULL
is	NULL
a	NULL
sequence-specific	NULL
DNA-binding	NULL
protein	NULL
which	NULL
recognizes	NULL
a	NULL
GTGGGAA	NULL
sequence	NULL
present	NULL
in	NULL
all	NULL
E2REs	NULL
and	NULL
interacts	NULL
with	NULL
a	NULL
27-amino-acid	NULL
domain	NULL
of	NULL
EBNA-2	NULL
that	NULL
includes	NULL
the	NULL
sequence	NULL
GPPWWPP	NULL
.	NULL

The	NULL
LMP1	NULL
promoter	NULL
has	NULL
Jx-binding	NULL
sites	NULL
at	NULL
-298	NULL
to	NULL
-290	NULL
and	NULL
-223	NULL
to	NULL
-213	NULL
.	NULL

Truncation	NULL
of	NULL
the	NULL
-298	NULL
to	NULL
-290	NULL
Jx	NULL
site	NULL
has	NULL
surprisingly	NULL
little	NULL
effect	NULL
on	NULL
EBNA-2	NULL
responsiveness	NULL
in	NULL
these	NULL
and	NULL
previous	NULL
experiments	NULL
.	NULL

Truncation	NULL
to	NULL
-214	NULL
removes	NULL
the	NULL
more-proximal	NULL
Jx	NULL
site	NULL
as	NULL
well	NULL
as	NULL
the	NULL
AMLA1	NULL
site	NULL
and	NULL
encroaches	NULL
on	NULL
the	NULL
LBF5	NULL
and	NULL
LBF6	NULL
sites	NULL
.	NULL

However	NULL
,	NULL
the	NULL
effect	NULL
on	NULL
EBNA-2	NULL
responsiveness	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
a	NULL
specific	NULL
mutation	NULL
in	NULL
the	NULL
J	NULL
Â«	NULL
-binding	NULL
site	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
in	NULL
EBNA-2	NULL
responsiveness	NULL
)	NULL
.	NULL

EBNA-2	NULL
can	NULL
also	NULL
interact	NULL
with	NULL
PU.1	NULL
,	NULL
and	NULL
this	NULL
interaction	NULL
is	NULL
likely	NULL
to	NULL
account	NULL
for	NULL
the	NULL
B-lymphocyte	NULL
specificity	NULL
of	NULL
the	NULL
EBNA-2	NULL
responsiveness	NULL
of	NULL
the	NULL
LMP1	NULL
promoter	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PU.1-binding	NULL
site	NULL
has	NULL
a	NULL
profound	NULL
effect	NULL
on	NULL
EBNA-2	NULL
responsiveness	NULL
.	NULL

However	NULL
,	NULL
the	NULL
PU.1	NULL
site	NULL
is	NULL
active	NULL
only	NULL
in	NULL
the	NULL
context	NULL
of	NULL
upstream	NULL
sequence	NULL
to	NULL
-215	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
LBF3-	NULL
and	NULL
LBF7-	NULL
and	NULL
at	NULL
least	NULL
part	NULL
of	NULL
the	NULL
LBF5-	NULL
and	NULL
LBF6-binding	NULL
sites	NULL
.	NULL

Which	NULL
of	NULL
these	NULL
factors	NULL
acts	NULL
in	NULL
conjunction	NULL
with	NULL
PU.1	NULL
to	NULL
convey	NULL
EBNA-2	NULL
responsiveness	NULL
is	NULL
not	NULL
known	NULL
.	NULL

An	NULL
epithelial-cell-specific	NULL
factor	NULL
,	NULL
LBF2	NULL
,	NULL
which	NULL
recognizes	NULL
a	NULL
-215	NULL
to	NULL
-192	NULL
site	NULL
is	NULL
also	NULL
identified	NULL
in	NULL
this	NULL
study	NULL
.	NULL

LBF2	NULL
could	NULL
account	NULL
for	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
-214	NULL
to	NULL
-144	NULL
LMP-1	NULL
promoter	NULL
sequence	NULL
in	NULL
the	NULL
high	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
in	NULL
epithelial	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

A	NULL
previously	NULL
described	NULL
silencer	NULL
is	NULL
also	NULL
shown	NULL
(	NULL
12	NULL
)	NULL
.	NULL

-150	NULL
-100	NULL
+1	NULL
may	NULL
be	NULL
provided	NULL
by	NULL
the	NULL
-215	NULL
LMP-1	NULL
promoter	NULL
CAT	NULL
construct	NULL
.	NULL

Interaction	NULL
of	NULL
one	NULL
of	NULL
these	NULL
factors	NULL
with	NULL
EBNA-2	NULL
may	NULL
account	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
-215	NULL
LMP-1	NULL
promoter	NULL
construct	NULL
,	NULL
or	NULL
a	NULL
less	NULL
direct	NULL
interaction	NULL
could	NULL
be	NULL
responsible	NULL
.	NULL

Experiments	NULL
to	NULL
detect	NULL
a	NULL
direct	NULL
interaction	NULL
of	NULL
LBF3	NULL
or	NULL
LBF7	NULL
with	NULL
EBNA-2	NULL
have	NULL
so	NULL
far	NULL
been	NULL
unsuccessful	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Although	NULL
EBNA-2	NULL
has	NULL
a	NULL
high	NULL
specific	NULL
affinity	NULL
for	NULL
Jx	NULL
and	NULL
all	NULL
EBNA-2-responsive	NULL
promoters	NULL
have	NULL
one	NULL
or	NULL
more	NULL
J-binding	NULL
sites	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
,	NULL
the	NULL
variable	NULL
importance	NULL
of	NULL
this	NULL
interaction	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
different	NULL
EZREs	NULL
is	NULL
surprising	NULL
.	NULL

Cp	NULL
E2RE	NULL
activity	NULL
is	NULL
absolutely	NULL
dependent	NULL
on	NULL
Jx	NULL
,	NULL
since	NULL
an	NULL
EBNA-2	NULL
WW	NULL
to	NULL
SS	NULL
or	NULL
SR	NULL
mutation	NULL
at	NULL
positions	NULL
319	NULL
and	NULL
320	NULL
,	NULL
which	NULL
disrupts	NULL
Jx	NULL
interaction	NULL
,	NULL
or	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
Jx	NULL
DNA-binding	NULL
site	NULL
independently	NULL
abolish	NULL
Cp	NULL
EBNA-2	NULL
responsiveness	NULL
(	NULL
16	NULL
,	NULL
19	NULL
,	NULL
20	NULL
,	NULL
25	NULL
,	NULL
48	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
same	NULL
EBNA-2	NULL
mutation	NULL
or	NULL
inactivating	NULL
or	NULL
deletional	NULL
mutations	NULL
of	NULL
the	NULL
LMP-1	NULL
-298	NULL
to	NULL
-290	NULL
and	NULL
-223	NULL
to	NULL
-213	NULL
IJk-binding	NULL
sites	NULL
result	NULL
in	NULL
only	NULL
a	NULL
twofold	NULL
decrease	NULL
in	NULL
LMP-1	NULL
transactivation	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
12	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
-335	NULL
to	NULL
-214	NULL
LMP-1	NULL
promoter	NULL
DNA	NULL
fragment	NULL
which	NULL
has	NULL
both	NULL
Jk	NULL
sites	NULL
conveys	NULL
only	NULL
low-level	NULL
activity	NULL
to	NULL
a	NULL
basal	NULL
TK	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EBNA-2	NULL
,	NULL
while	NULL
a	NULL
-214	NULL
to	NULL
-144	NULL
fragment	NULL
which	NULL
lacks	NULL
both	NULL
sites	NULL
showed	NULL
sevenfold	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EBNA-2	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Even	NULL
the	NULL
Cp	NULL
and	NULL
LMP-2	NULL
EZREs	NULL
can	NULL
not	NULL
be	NULL
limited	NULL
to	NULL
a	NULL
Jx	NULL
site	NULL
(	NULL
s	NULL
)	NULL
and	NULL
bind	NULL
other	NULL
,	NULL
as	NULL
yet	NULL
uncharacterized	NULL
,	NULL
factors	NULL
(	NULL
20	NULL
,	NULL
25	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
is	NULL
abundant	NULL
evidence	NULL
for	NULL
cooperative	NULL
functional	NULL
interactions	NULL
between	NULL
EBNA-2	NULL
and	NULL
sequence-specific	NULL
DNA-binding	NULL
proteins	NULL
besides	NULL
Jx	NULL
.	NULL

Computer	NULL
searches	NULL
of	NULL
each	NULL
E2RE	NULL
for	NULL
common	NULL
transcription	NULL
factor-binding	NULL
sites	NULL
has	NULL
,	NULL
however	NULL
,	NULL
turned	NULL
up	NULL
only	NULL
the	NULL
Jx-binding	NULL
sequence	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

The	NULL
central	NULL
importance	NULL
of	NULL
the	NULL
PU.1	NULL
site	NULL
in	NULL
LMP-1	NULL
EBNA-2	NULL
responsiveness	NULL
appears	NULL
to	NULL
explain	NULL
the	NULL
restriction	NULL
of	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
the	NULL
LMP1	NULL
promoter	NULL
to	NULL
B	NULL
lymphocytes	NULL
as	NULL
opposed	NULL
to	NULL
T	NULL
lymphocytes	NULL
or	NULL
epithelial	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
46	NULL
)	NULL
.	NULL

PU.1	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
number	NULL
of	NULL
lincage-specific	NULL
genes	NULL
in	NULL
macrophages	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
erythroid	NULL
cells	NULL
.	NULL

These	NULL
include	NULL
the	NULL
x	NULL
and	NULL
A	NULL
immunoglobulin	NULL
light	NULL
chain	NULL
,	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
,	NULL
and	NULL
B-globin	NULL
genes	NULL
(	NULL
10	NULL
,	NULL
15	NULL
,	NULL
35	NULL
,	NULL
50	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
PU.1	NULL
activation	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
unknown	NULL
,	NULL
although	NULL
,	NULL
as	NULL
is	NULL
seen	NULL
with	NULL
the	NULL
LMP-1	NULL
EZRE	NULL
,	NULL
their	NULL
activity	NULL
is	NULL
absolutely	NULL
dependent	NULL
on	NULL
PU.1	NULL
binding	NULL
.	NULL

PU.1	NULL
has	NULL
only	NULL
a	NULL
weak	NULL
activation	NULL
domain	NULL
in	NULL
a	NULL
proline-	NULL
,	NULL
glutamate-	NULL
,	NULL
serine-	NULL
,	NULL
and	NULL
threonine-rich	NULL
(	NULL
PEST	NULL
)	NULL
region	NULL
(	NULL
35	NULL
)	NULL
.	NULL

In	NULL
the	NULL
x	NULL
and	NULL
A	NULL
light-chain	NULL
enhancers	NULL
,	NULL
PU.1	NULL
activity	NULL
is	NULL
dependent	NULL
on	NULL
an	NULL
associated	NULL
factor	NULL
,	NULL
NF-EMS5	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
both	NULL
PU.1	NULL
and	NULL
an	NULL
adjacent	NULL
DNA	NULL
sequence	NULL
,	NULL
even	NULL
though	NULL
NF-EMS	NULL
can	NULL
not	NULL
itself	NULL
bind	NULL
DNA	NULL
(	NULL
10	NULL
,	NULL
35	NULL
)	NULL
.	NULL

NF-EMS	NULL
interacts	NULL
with	NULL
PU.1	NULL
through	NULL
the	NULL
PEST	NULL
domain	NULL
(	NULL
35	NULL
)	NULL
,	NULL
and	NULL
its	NULL
binding	NULL
is	NULL
dependent	NULL
on	NULL
phosphor-ylation	NULL
of	NULL
specific	NULL
PU.1	NULL
residues	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Like	NULL
Jx	NULL
,	NULL
PU.1	NULL
alone	NULL
could	NULL
not	NULL
convey	NULL
EBNA-2	NULL
responsiveness	NULL
to	NULL
the	NULL
LMP1	NULL
promoter	NULL
.	NULL

Although	NULL
the	NULL
PU.1	NULL
site	NULL
is	NULL
at	NULL
-169	NULL
to	NULL
-158	NULL
,	NULL
a	NULL
-205	NULL
to	NULL
+40	NULL
LMP1	NULL
promoter	NULL
was	NULL
not	NULL
EBNA-2	NULL
responsive	NULL
.	NULL

Addition	NULL
of	NULL
sequences	NULL
to	NULL
-215	NULL
rendered	NULL
the	NULL
fragment	NULL
significantly	NULL
EBNA-2	NULL
responsive	NULL
,	NULL
indicating	NULL
a	NULL
requirement	NULL
for	NULL
LBF3	NULL
,	NULL
LBF5	NULL
,	NULL
LBF6	NULL
,	NULL
or	NULL
LBF7	NULL
for	NULL
PU.1	NULL
responsiveness	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
a	NULL
-214	NULL
to	NULL
-144	NULL
fragment	NULL
is	NULL
sufficient	NULL
to	NULL
convey	NULL
EBNA-2	NULL
responsiveness	NULL
to	NULL
a	NULL
basal	NULL
TK	NULL
promoter	NULL
under	NULL
sensitive	NULL
assay	NULL
conditions	NULL
(	NULL
12	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
direct	NULL
high	NULL
level	NULL
interaction	NULL
between	NULL
a	NULL
GST-EBNA-2	NULL
fusion	NULL
protein	NULL
and	NULL
PU.1	NULL
.	NULL

The	NULL
EBNA-2	NULL
domain	NULL
responsible	NULL
for	NULL
this	NULL
interaction	NULL
(	NULL
amino	NULL
acids	NULL
310	NULL
to	NULL
376	NULL
)	NULL
can	NULL
also	NULL
interact	NULL
with	NULL
Jk	NULL
(	NULL
48	NULL
)	NULL
.	NULL

The	NULL
minimal	NULL
domain	NULL
for	NULL
Jk	NULL
interaction	NULL
consists	NULL
of	NULL
residues	NULL
310	NULL
to	NULL
337	NULL
(	NULL
48	NULL
)	NULL
,	NULL
and	NULL
that	NULL
domain	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
PU.1	NULL
interaction	NULL
,	NULL
suggesting	NULL
that	NULL
sequence	NULL
between	NULL
amino	NULL
acids	NULL
337	NULL
and	NULL
376	NULL
is	NULL
important	NULL
for	NULL
PU.1	NULL
interaction	NULL
.	NULL

The	NULL
physiologic	NULL
importance	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
PU.1-EBNA-2	NULL
interaction	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
absolute	NULL
dependence	NULL
of	NULL
the	NULL
LMP-1	NULL
E2RE	NULL
on	NULL
the	NULL
PU.1	NULL
site	NULL
.	NULL

Site-specific	NULL
mutational	NULL
analyses	NULL
of	NULL
the	NULL
PU.1-EBNA-2	NULL
310	NULL
to	NULL
376	NULL
interactive	NULL
domain	NULL
and	NULL
correlations	NULL
of	NULL
PU.1	NULL
association	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
with	NULL
EBNA-2	NULL
activity	NULL
in	NULL
LMP-1	NULL
transactivation	NULL
will	NULL
provide	NULL
further	NULL
important	NULL
tests	NULL
of	NULL
the	NULL
current	NULL
working	NULL
model	NULL
of	NULL
direct	NULL
EBNA-2-PU.1	NULL
interaction	NULL
.	NULL

From	NULL
a	NULL
more	NULL
formalistic	NULL
perspective	NULL
,	NULL
PU.1	NULL
potentiation	NULL
of	NULL
EBNA-2	NULL
effects	NULL
could	NULL
be	NULL
due	NULL
to	NULL
cooperation	NULL
with	NULL
other	NULL
EBNA-2-binding	NULL
proteins	NULL
such	NULL
as	NULL
Jk	NULL
in	NULL
assembly	NULL
of	NULL
an	NULL
EBNA-2	NULL
complex	NULL
at	NULL
the	NULL
LMP-1	NULL
promoter	NULL
,	NULL
to	NULL
an	NULL
effect	NULL
on	NULL
DNA	NULL
binding	NULL
so	NULL
that	NULL
EBNA-2	NULL
molecules	NULL
are	NULL
more	NULL
favorably	NULL
positioned	NULL
relative	NULL
to	NULL
the	NULL
promoter	NULL
(	NULL
as	NULL
has	NULL
been	NULL
suggested	NULL
for	NULL
high-mobility	NULL
group	NULL
domain	NULL
proteins	NULL
in	NULL
the	NULL
human	NULL
beta	NULL
interferon	NULL
promoter	NULL
[	NULL
9	NULL
]	NULL
)	NULL
,	NULL
to	NULL
enhanced	NULL
recruitment	NULL
of	NULL
specific	NULL
basal	NULL
factors	NULL
or	NULL
activators	NULL
,	NULL
or	NULL
to	NULL
effects	NULL
on	NULL
local	NULL
chromatin	NULL
or	NULL
nucleosome	NULL
architecture	NULL
.	NULL

Interaction	NULL
with	NULL
and	NULL
reversal	NULL
of	NULL
the	NULL
negative	NULL
effect	NULL
of	NULL
a	NULL
silencer	NULL
which	NULL
maps	NULL
between	NULL
-112	NULL
and	NULL
-55	NULL
is	NULL
also	NULL
a	NULL
possibility	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Genetic	NULL
and	NULL
biochemical	NULL
data	NULL
indicate	NULL
that	NULL
transcriptional	NULL
transactivation	NULL
by	NULL
EBNA-2	NULL
is	NULL
ultimately	NULL
mediated	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
acidic	NULL
domain	NULL
with	NULL
TFIIB	NULL
,	NULL
TAF40	NULL
,	NULL
and	NULL
TFIIH	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Multiple	NULL
EBNA-2	NULL
molecules	NULL
may	NULL
be	NULL
required	NULL
at	NULL
a	NULL
promoter	NULL
site	NULL
for	NULL
TFIIB	NULL
,	NULL
TAFA40	NULL
,	NULL
and	NULL
TFIIH	NULL
interactions	NULL
.	NULL

EMSAs	NULL
of	NULL
the	NULL
LMP-1	NULL
promoter	NULL
revealed	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
PU.1	NULL
,	NULL
a	NULL
distinct	NULL
but	NULL
much	NULL
less	NULL
abundant	NULL
factor	NULL
,	NULL
LBF4	NULL
,	NULL
binds	NULL
to	NULL
an	NULL
overlapping	NULL
recognition	NULL
site	NULL
and	NULL
is	NULL
found	NULL
in	NULL
B-	NULL
or	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

Methylation	NULL
interference	NULL
demonstrated	NULL
that	NULL
LBF4	NULL
recognized	NULL
the	NULL
same	NULL
core	NULL
guanosines	NULL
as	NULL
PU.1	NULL
,	NULL
yet	NULL
it	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
an	NULL
ets	NULL
family	NULL
protein	NULL
,	NULL
since	NULL
it	NULL
is	NULL
larger	NULL
than	NULL
any	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
mammalian	NULL
ets	NULL
protein	NULL
(	NULL
105	NULL
kDa	NULL
[	NULL
28	NULL
]	NULL
)	NULL
and	NULL
does	NULL
not	NULL
react	NULL
with	NULL
an	NULL
antibody	NULL
directed	NULL
at	NULL
the	NULL
conserved	NULL
ets	NULL
domain	NULL
.	NULL

The	NULL
recently	NULL
cloned	NULL
NF-AT	NULL
proteins	NULL
NF-ATc	NULL
and	NULL
NF-ATp	NULL
bind	NULL
to	NULL
a	NULL
similar	NULL
purine-rich	NULL
sequence	NULL
and	NULL
have	NULL
apparent	NULL
molecular	NULL
masses	NULL
of	NULL
105	NULL
to	NULL
120	NULL
kDa	NULL
,	NULL
respectively	NULL
(	NULL
29	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Although	NULL
LBF4	NULL
did	NULL
not	NULL
react	NULL
with	NULL
antibody	NULL
directed	NULL
to	NULL
rat	NULL
NF-ATp	NULL
,	NULL
LBF4	NULL
could	NULL
be	NULL
another	NULL
NF-AT	NULL
family	NULL
member	NULL
,	NULL
such	NULL
as	NULL
NF-ATc	NULL
(	NULL
33	NULL
)	NULL
.	NULL

NF-AT	NULL
is	NULL
characteristically	NULL
activated	NULL
by	NULL
B-	NULL
or	NULL
T-cell	NULL
activation	NULL
and	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
B-	NULL
or	NULL
T-cell	NULL
activation	NULL
and	NULL
cyclosporin	NULL
A	NULL
on	NULL
LBF4	NULL
would	NULL
be	NULL
of	NULL
interest	NULL
.	NULL

Although	NULL
LMP-1	NULL
promoter	NULL
constructs	NULL
with	NULL
an	NULL
LBF4-binding-site	NULL
mutation	NULL
were	NULL
still	NULL
EBNA-2	NULL
responsive	NULL
,	NULL
LBF4	NULL
could	NULL
be	NULL
important	NULL
in	NULL
regulating	NULL
LMP1	NULL
promoter	NULL
activity	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
that	NULL
are	NULL
stimulated	NULL
by	NULL
antigen	NULL
or	NULL
other	NULL
extracellular	NULL
ligands	NULL
.	NULL

AML1	NULL
also	NULL
binds	NULL
to	NULL
the	NULL
LMP-1	NULL
EZ2RE	NULL
but	NULL
has	NULL
little	NULL
effect	NULL
on	NULL
EBNA-2	NULL
responsiveness	NULL
in	NULL
B-lymphoma	NULL
cells	NULL
.	NULL

The	NULL
AML1	NULL
gene	NULL
was	NULL
identified	NULL
in	NULL
leukemic	NULL
chromosomal	NULL
translocations	NULL
that	NULL
fuse	NULL
the	NULL
N-terminal	NULL
portion	NULL
,	NULL
including	NULL
its	NULL
DNA-binding	NULL
do-main	NULL
,	NULL
with	NULL
various	NULL
other	NULL
cellular	NULL
genes	NULL
(	NULL
11	NULL
,	NULL
31	NULL
,	NULL
32	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Human	NULL
AML1	NULL
may	NULL
have	NULL
a	NULL
C-terminal	NULL
activation	NULL
domain	NULL
exon	NULL
that	NULL
would	NULL
be	NULL
homologous	NULL
to	NULL
the	NULL
C-terminal	NULL
activation	NULL
domain	NULL
of	NULL
the	NULL
murine	NULL
AML1	NULL
,	NULL
PEA2	NULL
(	NULL
2	NULL
)	NULL
.	NULL

This	NULL
exon	NULL
would	NULL
be	NULL
removed	NULL
in	NULL
the	NULL
translocated	NULL
AML1	NULL
gene	NULL
.	NULL

Interestingly	NULL
,	NULL
EBV	NULL
-transformed	NULL
B	NULL
cells	NULL
seem	NULL
to	NULL
have	NULL
a	NULL
greater	NULL
abundance	NULL
of	NULL
AML1	NULL
EMSA	NULL
activity	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
AML1	NULL
has	NULL
a	NULL
role	NULL
in	NULL
the	NULL
establishment	NULL
or	NULL
maintenance	NULL
of	NULL
the	NULL
EBV	NULL
growth-transformed	NULL
phenotype	NULL
.	NULL

The	NULL
only	NULL
other	NULL
cell-type-specific	NULL
LMP1	NULL
EZ2RE-binding	NULL
protein	NULL
identified	NULL
in	NULL
this	NULL
study	NULL
was	NULL
LBF2	NULL
,	NULL
which	NULL
recognizes	NULL
a	NULL
site	NULL
in	NULL
the	NULL
-215	NULL
to	NULL
-192	NULL
sequence	NULL
.	NULL

The	NULL
factor	NULL
appears	NULL
to	NULL
be	NULL
epithelial-cell-line	NULL
specific	NULL
.	NULL

LBF2	NULL
may	NULL
mediate	NULL
the	NULL
EBNA-2	NULL
independent	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
LMP-1	NULL
promoter	NULL
in	NULL
epithelial	NULL
cells	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
sequence	NULL
between	NULL
-214	NULL
and	NULL
-144	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
EBNA-2	NULL
transactivation	NULL
is	NULL
dependent	NULL
on	NULL
multiple	NULL
cellular	NULL
factors	NULL
and	NULL
that	NULL
it	NULL
may	NULL
physically	NULL
interact	NULL
with	NULL
at	NULL
least	NULL
two	NULL
separate	NULL
factors	NULL
on	NULL
the	NULL
same	NULL
promoter	NULL
suggests	NULL
a	NULL
complex	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
as	NULL
seen	NULL
with	NULL
other	NULL
viral	NULL
trans-activators	NULL
such	NULL
as	NULL
VP16	NULL
and	NULL
E1A	NULL
.	NULL

VP16	NULL
interacts	NULL
not	NULL
only	NULL
with	NULL
Oct-1	NULL
but	NULL
also	NULL
with	NULL
the	NULL
cellular	NULL
protein	NULL
complex	NULL
host	NULL
cell	NULL
factor	NULL
to	NULL
activate	NULL
herpes	NULL
simplex	NULL
virus	NULL
early-gene	NULL
promoters	NULL
(	NULL
23	NULL
,	NULL
26	NULL
,	NULL
37	NULL
,	NULL
39	NULL
)	NULL
.	NULL

E1A	NULL
interacts	NULL
with	NULL
seemingly	NULL
disparate	NULL
cellular	NULL
transcription	NULL
factors	NULL
(	NULL
26	NULL
)	NULL
,	NULL
which	NULL
probably	NULL
explains	NULL
its	NULL
greater	NULL
promiscuity	NULL
among	NULL
target	NULL
promoters	NULL
and	NULL
host	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
recent	NULL
identification	NULL
of	NULL
the	NULL
EZRE	NULL
targeting	NULL
factor	NULL
Jx	NULL
is	NULL
a	NULL
major	NULL
breakthrough	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
,	NULL
the	NULL
further	NULL
identification	NULL
of	NULL
a	NULL
role	NULL
for	NULL
PU.1	NULL
indicates	NULL
that	NULL
EBNA-2	NULL
transactivation	NULL
involves	NULL
more	NULL
than	NULL
simple	NULL
promoter	NULL
targeting	NULL
by	NULL
Jx	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
full	NULL
array	NULL
of	NULL
factor	NULL
interactions	NULL
essential	NULL
for	NULL
LMP1	NULL
expression	NULL
in	NULL
EBV-infected	NULL
cells	NULL
is	NULL
of	NULL
substantial	NULL
importance	NULL
in	NULL
understanding	NULL
the	NULL
biology	NULL
of	NULL
EBV	NULL
latent	NULL
infection	NULL
.	NULL

Since	NULL
LMP	NULL
-1	NULL
is	NULL
critical	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
EBV-induced	NULL
cell	NULL
transformations	NULL
(	NULL
21	NULL
)	NULL
,	NULL
factors	NULL
essential	NULL
for	NULL
LMP-1	NULL
expression	NULL
are	NULL
potential	NULL
targets	NULL
for	NULL
anti-LMP-1	NULL
pharmaceuticals	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Richard	NULL
Maki	NULL
for	NULL
anti-PU.1	NULL
antibody	NULL
,	NULL
PU.1	NULL
cDNA	NULL
,	NULL
and	NULL
helpful	NULL
discussions	NULL
and	NULL
to	NULL
Steve	NULL
Hiebert	NULL
for	NULL
anti-AML1	NULL
antibody	NULL
.	NULL

Lisa	NULL
Vara	NULL
and	NULL
Qian	NULL
Miao	NULL
provided	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

E.J	NULL
.	NULL

and	NULL
E.	NULL
Koh	NULL
were	NULL
predoctoral	NULL
fellows	NULL
of	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
(	NULL
E.J	NULL
.	NULL
)	NULL

and	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
E.	NULL
Koh	NULL
;	NULL
grant	NULL
GMO7753	NULL
)	NULL
.	NULL

G.M	NULL
.	NULL

and	NULL
S.R.G	NULL
.	NULL

were	NULL
postdoctoral	NULL
fellows	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
(	NULL
G.M	NULL
.	NULL
)	NULL

and	NULL
the	NULL
National	NULL
Foundation	NULL
for	NULL
Infectious	NULL
Disease	NULL
(	NULL
S.R.G	NULL
.	NULL
)	NULL

.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
grant	NULL
CA47006	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

EBNA-2	NULL
TRANSACTIVATION	NULL
OF	NULL
LMP-1	NULL
261	NULL
REFERENCES	NULL
.	NULL

Abbot	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
K.	NULL
Cadwallader	NULL
,	NULL
A.	NULL
Ricksten	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
L.	NULL
Rymo	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
virus-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2126-2134.	NULL
.	NULL

Bae	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Ogawa	NULL
,	NULL
M.	NULL
Maruyama	NULL
,	NULL
H.	NULL
Oka	NULL
,	NULL
M.	NULL
Satake	NULL
,	NULL
K.	NULL
Shigesada	NULL
,	NULL
N.	NULL
A.	NULL
Jenkins	NULL
,	NULL
D.	NULL
J.	NULL
Gilbert	NULL
,	NULL
N.	NULL
G.	NULL
Copeland	NULL
,	NULL
and	NULL
Y.	NULL
Ito	NULL
.	NULL

1994	NULL
.	NULL

PEBP2	NULL
Â«	NULL
B/mouse	NULL
AML1	NULL
consists	NULL
of	NULL
multiple	NULL
isoforms	NULL
that	NULL
possess	NULL
differential	NULL
transactivation	NULL
potentials	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:3242-3252.	NULL
.	NULL

Baer	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
T.	NULL
Bankier	NULL
,	NULL
M.	NULL
D.	NULL
Biggin	NULL
,	NULL
P.	NULL
L.	NULL
Deininger	NULL
,	NULL
P.	NULL
J.	NULL
Farrell	NULL
,	NULL
T.	NULL
J.	NULL
Gibson	NULL
,	NULL
G.	NULL
Hatfull	NULL
,	NULL
G.	NULL
S.	NULL
Hudson	NULL
,	NULL
S.	NULL
C.	NULL
Satchwell	NULL
,	NULL
C.	NULL
SÃ©guin	NULL
,	NULL
P.	NULL
S.	NULL
Tuffnell	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Barrell	NULL
.	NULL

1984	NULL
.	NULL

DNA	NULL
sequence	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
B95-8	NULL
Epstein-Barr	NULL
virus	NULL
genome	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
310:207-211.	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
DNA-binding	NULL
activity	NULL
in	NULL
an	NULL
apparently	NULL
cytoplasmic	NULL
precursor	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

Cell	NULL
53:211-217.	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
1992	NULL
.	NULL

Methylation	NULL
interference	NULL
assay	NULL
for	NULL
analysis	NULL
of	NULL
DNA	NULL
protein	NULL
interactions	NULL
,	NULL
p.	NULL
12.8-12.10	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struh	NULL
!	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Short	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

.	NULL

Calender	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Billaud	NULL
,	NULL
J.	NULL
P.	NULL
Aubry	NULL
,	NULL
J.	NULL
Banchereau	NULL
,	NULL
M.	NULL
Vuillaume	NULL
,	NULL
and	NULL
G.	NULL
Lenoir	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
markers	NULL
on	NULL
in	NULL
vitro	NULL
infedction	NULL
of	NULL
EBV-negative	NULL
B-lymphoma	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:8060-8064.	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
L	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
domain	NULL
essential	NULL
for	NULL
transformation	NULL
is	NULL
a	NULL
direct	NULL
transcriptional	NULL
activator	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5880-5885.	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
J.	NULL
Mannick	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
is	NULL
a	NULL
key	NULL
determinant	NULL
of	NULL
lymphocyte	NULL
transformation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:9558-9562.	NULL
.	NULL

Du	NULL
,	NULL
W.	NULL
,	NULL
D.	NULL
Thanos	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1993	NULL
.	NULL

Mechanisms	NULL
of	NULL
transcriptional	NULL
synergism	NULL
between	NULL
distinct	NULL
virus-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
74:887-898	NULL
.	NULL

Eisenbeis	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
and	NULL
U.	NULL
Storb	NULL
.	NULL

1993	NULL
.	NULL

PU.1	NULL
is	NULL
a	NULL
component	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
which	NULL
binds	NULL
an	NULL
essential	NULL
site	NULL
in	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
A2-4	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6452-6461	NULL
.	NULL

Erickson	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Gao	NULL
,	NULL
K.	NULL
S.	NULL
Chang	NULL
,	NULL
T.	NULL
Look	NULL
,	NULL
E.	NULL
Whisenant	NULL
,	NULL
S.	NULL
Raimondi	NULL
,	NULL
R.	NULL
Lasher	NULL
,	NULL
J.	NULL
Trujillo	NULL
,	NULL
J.	NULL
Rowley	NULL
,	NULL
and	NULL
H.	NULL
Drabkin	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
breakpoints	NULL
in	NULL
the	NULL
1	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
isolation	NULL
of	NULL
a	NULL
fusion	NULL
transcript	NULL
,	NULL
AML1/ETO	NULL
,	NULL
with	NULL
similarity	NULL
to	NULL
Drosophila	NULL
segmentation	NULL
gene	NULL
,	NULL
runt	NULL
.	NULL

Blood	NULL
80:1825-1831	NULL
.	NULL

Fabraeus	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
Jansson	NULL
,	NULL
A.	NULL
Sfoblom	NULL
,	NULL
T.	NULL
Nilsson	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
L.	NULL
Rymo	NULL
.	NULL

1993	NULL
.	NULL

Cell	NULL
phenotype-dependent	NULL
control	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
gene	NULL
regulatory	NULL
sequences	NULL
.	NULL

Virology	NULL
195:71-80	NULL
.	NULL

Fennewald	NULL
,	NULL
S.	NULL
,	NULL
V.	NULL
van	NULL
Santen	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
a	NULL
messenger	NULL
RNA	NULL
transcribed	NULL
in	NULL
latent	NULL
growth	NULL
transforming	NULL
virus	NULL
infection	NULL
indicates	NULL
that	NULL
it	NULL
may	NULL
encode	NULL
a	NULL
membrane	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

51:411-419	NULL
.	NULL

Furukawa	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Maruyama	NULL
,	NULL
M.	NULL
Kawaichi	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Drosophila	NULL
homolog	NULL
of	NULL
the	NULL
immunoglobulin	NULL
recombination	NULL
signal-binding	NULL
protein	NULL
regulates	NULL
peripheral	NULL
nervous	NULL
system	NULL
development	NULL
.	NULL

Cell	NULL
69:1191-1197	NULL
.	NULL

Galson	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
J.	NULL
O.	NULL
Hensold	NULL
,	NULL
T.	NULL
R.	NULL
Bishop	NULL
,	NULL
M.	NULL
Schalling	NULL
,	NULL
A.	NULL
D.	NULL
D'Andrea	NULL
,	NULL
C.	NULL
Jones	NULL
,	NULL
P.	NULL
E.	NULL
Auron	NULL
,	NULL
and	NULL
D.	NULL
E.	NULL
Housman	NULL
.	NULL

1993	NULL
.	NULL

Mouse	NULL
-globin	NULL
DNA-binding	NULL
protein	NULL
B1	NULL
is	NULL
identical	NULL
to	NULL
a	NULL
proto-oncogene	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
Spi-1/	NULL
PU.1	NULL
,	NULL
and	NULL
is	NULL
restricted	NULL
in	NULL
expression	NULL
to	NULL
hematopoietic	NULL
cells	NULL
and	NULL
the	NULL
testis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:2929-2941	NULL
.	NULL

Grossman	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
E.	NULL
Johannsen	NULL
,	NULL
X.	NULL
Tong	NULL
,	NULL
R.	NULL
Yalamanchili	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivator	NULL
is	NULL
directed	NULL
to	NULL
response	NULL
elements	NULL
by	NULL
the	NULL
Jx	NULL
recombination	NULL
signal	NULL
binding	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7568-7572	NULL
.	NULL

Hamaguchi	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Yamamoto	NULL
,	NULL
H.	NULL
Iwanari	NULL
,	NULL
S.	NULL
Maruyama	NULL
,	NULL
T.	NULL
Furukawa	NULL
,	NULL
N.	NULL
Matsunami	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1992	NULL
.	NULL

Biochemical	NULL
and	NULL
immunological	NULL
characterization	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
protein	NULL
(	NULL
RBP-J	NULL
)	NULL
to	NULL
mouse	NULL
Jx	NULL
recombination	NULL
signal	NULL
sequence	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

112:314-320	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1989	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
immortalizing	NULL
functions	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
340:393-397	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
P.	NULL
D.	NULL
Ling	NULL
,	NULL
S.	NULL
D.	NULL
Hayward	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Peterson	NULL
.	NULL

1994	NULL
.	NULL

Mediation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
EBNAZ	NULL
transactivation	NULL
by	NULL
recombination	NULL
signal-binding	NULL
protein	NULL
Jx	NULL
.	NULL

Science	NULL
265:92-95	NULL
.	NULL

Jin	NULL
,	NULL
X.	NULL
W.	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
critical	NULL
cis	NULL
elements	NULL
involved	NULL
in	NULL
mediating	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2-dependent	NULL
activity	NULL
of	NULL
an	NULL
enhancer	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
viral	NULL
BamHI	NULL
C	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:2846-2852	NULL
.	NULL

Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
K.	NULL
M.	NULL
Izumi	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
is	NULL
essential	NULL
for	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:9150-9154	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Kristie	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
octamer-binding	NULL
proteins	NULL
form	NULL
multi-protein-DNA	NULL
complexes	NULL
with	NULL
the	NULL
HSV	NULL
alpha	NULL
TIF	NULL
regulatory	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:4229-4238	NULL
.	NULL

262	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

JOHANNSEN	NULL
ET	NULL
AL	NULL
.	NULL

Laimins	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
P.	NULL
Gruss	NULL
,	NULL
R.	NULL
Pozzatti	NULL
,	NULL
and	NULL
G.	NULL
Khoury	NULL
.	NULL

1984	NULL
.	NULL

Characterization	NULL
of	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
Moloney	NULL
murine	NULL
sarcoma	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

49:183-189	NULL
.	NULL

Ling	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
D.	NULL
R.	NULL
Rawlins	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
immortalizing	NULL
protein	NULL
EBNA-2	NULL
is	NULL
targeted	NULL
to	NULL
DNA	NULL
by	NULL
a	NULL
cellular	NULL
enhancer-binding	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:9237-9241	NULL
.	NULL

Liu	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
M.	NULL
Green	NULL
.	NULL

1994	NULL
.	NULL

Promoter	NULL
targeting	NULL
by	NULL
adenovirus	NULL
Ela	NULL
through	NULL
interaction	NULL
with	NULL
different	NULL
cellular	NULL
DNA-binding	NULL
domains	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
368:520-525	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
G.	NULL
Shutz	NULL
.	NULL

1987	NULL
.	NULL

CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15:5490	NULL
.	NULL

Macleod	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
Leprince	NULL
,	NULL
and	NULL
D.	NULL
Stehelin	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
ets	NULL
gene	NULL
family	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:251-256	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1993	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
eyclosporin-sensitive	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
.	NULL

Science	NULL
262:750-754	NULL
.	NULL

Meyers	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
R.	NULL
Downing	NULL
,	NULL
and	NULL
S.	NULL
W.	NULL
Hiebert	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
AML-1	NULL
and	NULL
the	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
translocation	NULL
protein	NULL
(	NULL
AML-1/ETO	NULL
)	NULL
as	NULL
sequence-specific	NULL
DNA-binding	NULL
proteins	NULL
:	NULL
the	NULL
runt	NULL
homology	NULL
domain	NULL
is	NULL
required	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6336-6345	NULL
.	NULL

Mitani	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Ogawa	NULL
,	NULL
T.	NULL
Tanaka	NULL
,	NULL
H.	NULL
Miyoshi	NULL
,	NULL
M.	NULL
Kurokawa	NULL
,	NULL
H.	NULL
Mano	NULL
,	NULL
Y.	NULL
Yazaki	NULL
,	NULL
M.	NULL
Ohki	NULL
,	NULL
and	NULL
H.	NULL
Hirai	NULL
.	NULL

1994	NULL
.	NULL

Generation	NULL
of	NULL
the	NULL
AML1-EVI-1	NULL
fusion	NULL
gene	NULL
in	NULL
the	NULL
t	NULL
(	NULL
3	NULL
;	NULL
21	NULL
)	NULL
(	NULL
q26	NULL
;	NULL
q22	NULL
)	NULL
causes	NULL
blastic	NULL
crisis	NULL
in	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:504-510	NULL
.	NULL

Miyoshi	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Shimizu	NULL
,	NULL
T.	NULL
Kozu	NULL
,	NULL
N.	NULL
Maseki	NULL
,	NULL
Y.	NULL
Kaneko	NULL
,	NULL
and	NULL
M.	NULL
Ohki	NULL
.	NULL

1991.	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
breakpoints	NULL
on	NULL
chromosome	NULL
21	NULL
in	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
are	NULL
clustered	NULL
within	NULL
a	NULL
limited	NULL
region	NULL
of	NULL
a	NULL
single	NULL
gene	NULL
,	NULL
AML1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:10431-10434	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
369:497-502	NULL
.	NULL

Nucifora	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
R.	NULL
Begy	NULL
,	NULL
P.	NULL
Erickson	NULL
,	NULL
H.	NULL
A.	NULL
Drabkin	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Rowley	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
3	NULL
;	NULL
21	NULL
translocation	NULL
in	NULL
myelodysplasia	NULL
results	NULL
in	NULL
a	NULL
fusion	NULL
transcript	NULL
between	NULL
the	NULL
AML1	NULL
gene	NULL
and	NULL
the	NULL
gene	NULL
for	NULL
EAP	NULL
,	NULL
a	NULL
highly	NULL
conserved	NULL
protein	NULL
associated	NULL
with	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
small	NULL
RNA	NULL
EBER1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7784-7788	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
R.	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1992	NULL
.	NULL

PU.1	NULL
recruits	NULL
a	NULL
second	NULL
nuclear	NULL
factor	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
x	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:368-378	NULL
.	NULL

Pongubala	NULL
,	NULL
J.	NULL
M.	NULL
R.	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
S.	NULL
Nagulapalli	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Atchison	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
PU.1	NULL
phosphor-ylation	NULL
on	NULL
interaction	NULL
with	NULL
NF-EMS5	NULL
and	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
259:1622-1625	NULL
.	NULL

Sadowski	NULL
,	NULL
L	NULL
,	NULL
J.	NULL
Ma	NULL
,	NULL
S.	NULL
Triezenberg	NULL
,	NULL
and	NULL
M.	NULL
Ptashne	NULL
.	NULL

1988	NULL
.	NULL

GAL4-VP16	NULL
is	NULL
an	NULL
unusually	NULL
potent	NULL
transcriptional	NULL
activator	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
335:563-564	NULL
.	NULL

Schweisguth	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Posakony	NULL
.	NULL

1992	NULL
.	NULL

Suppressor	NULL
of	NULL
Hairless	NULL
,	NULL
the	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

Drosophila	NULL
homolog	NULL
of	NULL
the	NULL
mouse	NULL
recombination	NULL
signal-binding	NULL
protein	NULL
gene	NULL
,	NULL
controls	NULL
sensory	NULL
organ	NULL
cell	NULL
fates	NULL
.	NULL

Cell	NULL
69:1199-1212	NULL
.	NULL

Stern	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Tanaka	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Oct-1	NULL
homeodomain	NULL
directs	NULL
formation	NULL
of	NULL
a	NULL
multiprotein-DNA	NULL
complex	NULL
with	NULL
the	NULL
HSV	NULL
transactivator	NULL
VP16	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
341:624-630	NULL
.	NULL

Tong	NULL
,	NULL
X.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
C.	NULL
J.	NULL
Thut	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
is	NULL
similar	NULL
to	NULL
VP16	NULL
in	NULL
interaction	NULL
with	NULL
TFIIB	NULL
,	NULL
TAF40	NULL
,	NULL
and	NULL
RPA7O	NULL
,	NULL
but	NULL
not	NULL
with	NULL
TBP	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Tsang	NULL
,	NULL
S.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
K.	NULL
M.	NULL
Izumi	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
cis-acting	NULL
element	NULL
mediating	NULL
EBNA-2	NULL
transactivation	NULL
of	NULL
latent	NULL
infection	NULL
membrane	NULL
protein	NULL
association	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:6765-6771	NULL
.	NULL

Tun	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Hamaguchi	NULL
,	NULL
N.	NULL
Mat	NULL
i	NULL
,	NULL
T.	NULL
Furukawa	NULL
,	NULL
T.	NULL
Honjo	NULL
,	NULL
and	NULL
M.	NULL
Kawaichi	NULL
.	NULL

1994	NULL
.	NULL

Recognition	NULL
sequence	NULL
of	NULL
a	NULL
highly	NULL
conserved	NULL
DNA	NULL
binding	NULL
protein	NULL
RBP-J	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

22:965-971	NULL
.	NULL

Ushiro	NULL
,	NULL
H.	NULL
,	NULL
Y.	NULL
Yokoyama	NULL
,	NULL
and	NULL
Y.	NULL
Shizuta	NULL
.	NULL

1987	NULL
.	NULL

Purification	NULL
and	NULL
characterization	NULL
of	NULL
poly	NULL
(	NULL
ADP-ribose	NULL
)	NULL
synthetase	NULL
from	NULL
human	NULL
placenta	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262:2352-2357	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
C.	NULL
Sample	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
R.	NULL
Murray	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP1	NULL
)	NULL
and	NULL
nuclear	NULL
proteins	NULL
2	NULL
and	NULL
3C	NULL
are	NULL
effectors	NULL
of	NULL
phenotypic	NULL
changes	NULL
in	NULL
B	NULL
lymphocytes	NULL
:	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
cooperatively	NULL
induce	NULL
CD23	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2309-2318	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Kikutani	NULL
,	NULL
S.	NULL
F.	NULL
Tsang	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
transactivates	NULL
a	NULL
cis-acting	NULL
CD23	NULL
DNA	NULL
element	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4101-4106	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
Tsang	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
J.	NULL
I	NULL
Cohen	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivates	NULL
latent	NULL
membrane	NULL
protein	NULL
LMP1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3407-3416	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
,	NULL
Q.	NULL
Wang	NULL
,	NULL
B.	NULL
E.	NULL
Crute	NULL
,	NULL
I.	NULL
N.	NULL
Melnikova	NULL
,	NULL
S.	NULL
R.	NULL
Keller	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Speck	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
subunits	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
and	NULL
murine	NULL
leukemia	NULL
virus	NULL
core-binding	NULL
factor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3324-3339	NULL
.	NULL

Yalamanchilli	NULL
,	NULL
R.	NULL
,	NULL
X.	NULL
Tong	NULL
,	NULL
S.	NULL
R.	NULL
Grossman	NULL
,	NULL
E.	NULL
Johannsen	NULL
,	NULL
G.	NULL
Mosialos	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1994	NULL
.	NULL

Genetic	NULL
and	NULL
biochemical	NULL
evidence	NULL
that	NULL
EBNA-2	NULL
interaction	NULL
with	NULL
a	NULL
63-kilodalton	NULL
cellular	NULL
GTG-binding	NULL
protein	NULL
is	NULL
essential	NULL
for	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Virology	NULL
204:634-641	NULL
.	NULL

Young	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Alfieri	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
H.	NULL
Evans	NULL
,	NULL
C.	NULL
O'Hara	NULL
,	NULL
K.	NULL
C.	NULL
Anderson	NULL
,	NULL
J.	NULL
Ritz	NULL
,	NULL
R.	NULL
S.	NULL
Shapiro	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
J.	NULL
I.	NULL
Cohen	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
transformation-associated	NULL
genes	NULL
in	NULL
tissues	NULL
of	NULL
patients	NULL
with	NULL
EBV	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

321	NULL
:	NULL
1080-1085	NULL
.	NULL

Zhang	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
J.	NULL
Hetherington	NULL
,	NULL
H.	NULL
Chen	NULL
,	NULL
and	NULL
D.	NULL
G.	NULL
Tenen	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
macrophage	NULL
transcription	NULL
factor	NULL
PU.1	NULL
directs	NULL
tissue-specific	NULL
expression	NULL
of	NULL
the	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:373-381	NULL
.	NULL

Zimber-Strobl	NULL
,	NULL
U.	NULL
,	NULL
E.	NULL
Kremmer	NULL
,	NULL
F.	NULL
Grasser	NULL
,	NULL
G.	NULL
Marschall	NULL
,	NULL
G.	NULL
Laux	NULL
,	NULL
and	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
interacts	NULL
with	NULL
an	NULL
EBNAZ	NULL
responsive	NULL
cis-clement	NULL
of	NULL
the	NULL
terminal	NULL
protein	NULL
1	NULL
gene	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:167-175	NULL
.	NULL

